US20030143616A1 - Addressable protein arrays - Google Patents
Addressable protein arrays Download PDFInfo
- Publication number
- US20030143616A1 US20030143616A1 US10/348,627 US34862703A US2003143616A1 US 20030143616 A1 US20030143616 A1 US 20030143616A1 US 34862703 A US34862703 A US 34862703A US 2003143616 A1 US2003143616 A1 US 2003143616A1
- Authority
- US
- United States
- Prior art keywords
- solid support
- nucleic acid
- protein
- protein fusion
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
- C03C17/28—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material
- C03C17/30—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
- C03C17/34—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions
- C03C17/3405—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions with at least two coatings of organic materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/552—Glass or silica
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00378—Piezo-electric or ink jet dispensers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00387—Applications using probes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00529—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00608—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/0061—The surface being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/00626—Covalent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00632—Introduction of reactive groups to the surface
- B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
- B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
- B01J2219/00662—Two-dimensional arrays within two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00677—Ex-situ synthesis followed by deposition on the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00686—Automatic
- B01J2219/00691—Automatic using robots
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00702—Processes involving means for analysing and characterising the products
- B01J2219/00707—Processes involving means for analysing and characterising the products separated from the reactor apparatus
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00729—Peptide nucleic acids [PNA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- the invention relates to fixed arrays of nucleic acid-protein fusions and, in particular, RNA-protein fusions, on solid supports.
- proteins are known to interact specifically with other molecules based on the three-dimensional shapes and electronic distributions of those molecules.
- proteins interact selectively with other proteins, with nucleic acids, and with small-molecules.
- Modem pharmaceutical research relies on the study of these interactions; the development of new drugs depends on the discovery of compounds that bind specifically to biologically important molecules.
- proteins cannot always be easily attached to the planar surfaces traditionally used to make other fixed arrays, such as nucleic acid microchips. More importantly, because proteins can interact with the functional groups on the surfaces of these supports, the proximity of the protein to the surface can lead to disruption of the protein structure.
- the invention features a solid support including an array of immobilized capture probes; each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion is bound (for example, hybridized or covalently bound).
- the nucleic acid-protein fusion is an RNA-protein fusion
- the protein component is encoded by the nucleic acid (for example, the RNA).
- the spacer group can include a polyalkylene oxide, for example, polyethylene oxide.
- a preferred spacer group includes hexaethylene oxide.
- the capture probe may also include a photocleavable linker.
- the oligonucleotide sequence can include a modified base, such as 5-propyne pyrimidine. It can also include an internucleotide analog (such as 3′-phosphoramidate) or a carbohydrate modification (such as a 2′-O-methyl group).
- the nucleic acid-protein fusion can include a hybridization tag sequence.
- the hybridization tag sequence can also include a modified base, an intemucleotide analog, or a carbohydrate modification.
- the capture probe further includes a reactive moiety (for example, a nucleophilic group), such as a primary amino group.
- a reactive moiety for example, a nucleophilic group
- the nucleic acid-protein fusion is covalently linked to the capture probe (for example, by photo-crosslinking); in one preferred approach, this is accomplished by including one or more psoralen moieties in the capture probe or in the capture probe-fusion hybridization reaction mixture.
- a preferred solid support is a glass or silica-based chip.
- the invention features a solid support including an array of immobilized capture probes; each of the capture probes is attached to the surface of the solid support through a non-nucleosidic spacer group, and each of the capture probes includes an oligonucleotide sequence to which a nucleic acid-protein fusion (for example, an RNA-protein fusion) is bound (for example, hybridized or covalently bound).
- a nucleic acid-protein fusion for example, an RNA-protein fusion
- the invention features a solid support including an array of immobilized capture probes; each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a ribosome display particle is bound (for example, hybridized or covalently bound).
- the invention features a method for preparing a solid support.
- the method includes the steps of: (a) preparing a capture probe by linking a spacer group to an oligonucleotide sequence; (b) attaching the capture probe to the solid support; and (c) binding (for example, hybridizing or covalently binding) a nucleic acid-protein fusion (for example, an RNA-protein fusion) to the capture probe.
- a nucleic acid-protein fusion for example, an RNA-protein fusion
- the invention also features a second general method for preparing a solid support.
- This method includes the steps of: (a) attaching a spacer group to a surface of the solid support; (b) attaching a bifunctional linker to the spacer group; (c) attaching a capture probe to the bifunctional linker; and (d) binding (for example, hybridizing or covalently binding) a nucleic acid-protein fusion (for example, an RNA-protein fusion) to the capture probe.
- the invention features a method for detecting an interaction between a protein and a compound.
- the method includes the steps of: (a) providing a solid support including an array of immobilized capture probes, where each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion is bound (for example, hybridized or covalently bound); (b) contacting the solid support with a candidate compound under conditions which allow an interaction between the protein portion of the nucleic acid-protein fusion and the compound; and (c) analyzing the solid support for the presence of the compound as an indication of an interaction between the protein and the compound.
- the invention features another method for detecting an interaction between a protein and a compound; this method involves the steps of: (a) providing a population of nucleic acid-protein fusions; (b) contacting the population of nucleic acid-protein fusions with a candidate compound under conditions which allow an interaction between the protein portion of the nucleic acid-protein fusion and the compound; (c) contacting the product of step (b) with a solid support that includes an array of immobilized capture probes, each of the capture probes including a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion binds (for example, hybridizes or covalently binds); and (d) analyzing the solid support for the presence of the compound as an indication of an interaction between the protein and the compound.
- the nucleic acid-protein fusion is an RNA-protein fusion.
- the compound is labeled.
- Compounds that can be screened using these methods include, without limitation, proteins, drugs, therapeutics, enzymes, and nucleic acids.
- the invention features an array (for example, an addressable array) of nucleic acid-protein fusions including at least 10 2 different fusions/cm 2 .
- the nucleic acid-protein fusions are RNA-protein fusions, and the array includes at least 10 4 different fusions/cm 2 .
- the invention features a method for generating an addressable array of molecules.
- the method involves: (a) providing a solid support on which an array of nucleic acid molecules is immobilized; (b) contacting the solid support with a population of addressable molecules; and (c) allowing the addressable molecules to orient themselves on the solid support by sequence-dependent recognition and binding of the immobilized nucleic acid molecules.
- the addressable array of molecules is an array of nucleic acid-protein fusions (for example, an array of RNA-protein fusions); the addressable molecules orient themselves on the solid support by base pairing (for example, hybridization) with the immobilized nucleic acid molecules; the solid support is a glass or silica-based chip; and the nucleic acid molecules immobilized on the solid support are capture probes, each including a non-nucleosidic spacer group and an oligonucleotide sequence to which the addressable molecule binds.
- an “array” is meant a fixed pattern of immobilized objects on a solid surface or membrane.
- the array is made up of nucleic acid-protein fusion molecules (for example, RNA-protein fusion molecules) bound to capture nucleic acid sequences which themselves are immobilized on the solid surface or membrane.
- the array preferably includes at least 10 2 , more preferably at least 10 3 , and most preferably at least 10 4 different fusions, and these fusions are preferably arrayed on a 125 ⁇ 80 mm, and more preferably on a 10 ⁇ 10 mm, surface.
- an “addressable array” is meant that the locations, or addresses, on the solid support of the members of the array (for example, the nucleic acid-protein fusions) are known; the members of the array are referred to as “addressable molecules” and are utilized in methods for screening for subsequent molecular interactions (for example, for screening for interactions between the addressable nucleic acid-protein fusions and candidate therapeutics).
- nucleic acid-protein fusion is meant a nucleic acid covalently bonded to a protein.
- nucleic acid is meant any two or more covalently bonded nucleotides or nucleotide analogs or derivatives.
- this term includes, without limitation, DNA, RNA, and PNA.
- protein is meant any two or more amino acids, or amino acid analogs or derivatives, joined by peptide or peptoid bond(s), regardless of length or post-translational modification. As used herein, this term includes, without limitation, proteins, peptides, and polypeptides.
- hybridization tag is meant a non-coding oligonucleotide sequence that differs sufficiently in sequence from other nucleic acid sequences in a given population or reaction mixture that significant cross-hybridization does not occur.
- hybridization tags When multiple hybridization tags are utilized in a single reaction mixture, these tags also preferably differ in sequence from one another such that each has a unique binding partner under the conditions employed.
- a “population” is meant more than one molecule.
- solid support any solid surface including, without limitation, any chip (for example, silica-based, glass, or gold chip), glass slide, membrane, bead, solid particle (for example, agarose, sepharose, or magnetic bead), column (or column material), test tube, or microtiter dish.
- FIG. 1 is a drawing showing the silylation of a glass surface, the derivatization of the resulting amino groups, and the attachment of a capture probe to the modified surface.
- FIG. 2 is a drawing illustrating a capture probe containing a non-nucleosidic spacer group and a reactive moiety.
- FIG. 3 is a schematic diagram of the layout of the FLAG and HA11 fusion chip capture probes utilized in FIGS. 4 and 5.
- t7, tag, au1, au5, flag, ha1, irs, and kt3 represent the capture probes CPt7 (positive control), CPtag (positive control), CPau1 (negative control), CPau5 (negative control), CPflag, CPha11, CPirs (negative control), and CPkt3 (negative control), respectively.
- FIG. 4 is a phosphorimage demonstrating hybridization of nucleic acid-protein fusions (FLAG and HA11) to capture probes immobilized on a chip.
- FIG. 5 is a fluorimage demonstrating hybridization of nucleic acid-protein fusions (FLAG and HA11) to capture probes immobilized on a chip and subsequent recognition with anti-HA11 monoclonal antibodies.
- FIG. 6 is a schematic diagram of the layout of the Myc fusion chip capture probes utilized in FIGS. 7 and 8.
- capture probes CP01, CP33, CP80, CP125, CPmm, and CPns were arranged on the chip as follows: CP01 at locations A1, B1, C1, A4, B4, and C4; CP33 at locations D1, E1, F1, D4, E4, and F4; CP80 at locations A2, B2, C2, A5, B5, and C5; CP125 at locations D2, E2, F2, D5, E5, and F5; CPmm at locations A3, B3, C3, A6, B6, and C6; and CPns at locations D3, E3, F3, D6, E6, and F6.
- FIG. 7 is a phosphorimage demonstrating hybridization of nucleic acid-protein fusions (Myc) to capture probes immobilized on a chip.
- FIG. 8 is a fluorimage demonstrating hybridization of nucleic acid-protein fusions (Myc) to capture probes immobilized on a chip and subsequent recognition with anti-Myc monoclonal antibodies.
- the invention features support-based, addressable arrays of proteins, and methods for preparing and using these arrays.
- the arrays are prepared by fixing oligonucleotide sequences, the capture probes (or capture oligos), to a support in a defined array.
- the capture probes are then used to bind nucleic acid-protein fusions, such as RNA-protein fusions.
- binding may occur through base pairing (for example, through Watson-Crick base pairing, pseudo Watson-Crick base pairing involving modified bases, or Hoogsteen base pairing) between the nucleic acid component of the fusion and a complementary capture probe, or may occur through any other type of sequence-dependent recognition and binding of the capture probe (including, without limitation, polyamide-mediated nucleic acid groove binding or specific binding by nucleic acid-binding proteins such as transcription factors).
- base pairing for example, through Watson-Crick base pairing, pseudo Watson-Crick base pairing involving modified bases, or Hoogsteen base pairing
- sequence-dependent recognition and binding of the capture probe including, without limitation, polyamide-mediated nucleic acid groove binding or specific binding by nucleic acid-binding proteins such as transcription factors.
- a variety of materials can be used as the solid support. Examples of such materials include polymers (e.g., plastics), aminated surfaces, gold coated surfaces, nylon membranes, polyacrylamide pads deposited on solid surfaces, silicon, silicon-glass (e.g., microchips), silicon wafers, and glass (e.g., microscope slides). Microchips, and particularly glass microchips, represent a preferred solid support surface.
- the surface is not already aminated, it can be modified to provide a layer of amino groups.
- a glass microscope slide can be treated with a silylating agent such as trialkoxyaminosilane to provide a surface of primary amino groups that exists as a monolayer or 3-8 molecular layers. This reaction is illustrated in FIG. 1.
- the silane-treated surface is then derivatized with a homobifunctional or heterobifunctional linker that permits the attachment of oligonucleotides at discrete positions.
- Phenylene 1,4-diisothiocyanate is a useful homobifunctional linker; amino-surfaces derivatized with this reagent have isothiocyanate functionalities that are available to covalently react with the primary amino groups on the termini of oligonucleotides to form stable thiourea bonds, as shown in FIG. 1.
- the capture probes i.e., the oligonucleotide sequences that are to be attached to the surface, are selected from the reverse-complements of the nucleic acid components of the nucleic acid-protein fusions (the targets).
- Capture probes preferably have between 5 and 30 nucleotide units, and more preferably have about 20 nucleotide units.
- Considerations for the selection of the exact sequence for a particular capture probe include melting temperature (Tm), interference from competing target sequences, and potential secondary structure in the target sequence.
- Tm melting temperature
- each unique capture probe has the same Tm, i.e., they are isoenergetic, so a single hybridization and washing temperature can be used successfully for all capture-target pairs.
- Commercially available computer programs e.g., Oligo 4.0
- Oligo 4.0 can be used to help identify sets of capture probes with similar thermodynamic properties based on nearest neighbor treatments.
- the capture probes are modified before they are attached to the surface.
- One or more non-nucleosidic spacers such as polyethylene oxide, are added to the terminus of the oligo. Preferably, 1-20 spacers and, most preferably, 4 spacers are utilized. These spacers may be added to either the 5′ or preferably the 3′ end of the oligonucleotide.
- a nucleophilic moiety is then attached to the spacer group. The result is a derivatized capture probe, as shown in FIG. 2.
- a preferred spacer monomer includes hexaethylene oxide.
- Non-nucleosidic spacers are preferred over nucleosidic spacers, such as poly-T, because non-nucleosidic spacers have greater flexibility. In addition, their physical properties can be tailored relatively easily, and it is possible to minimize specific and non-specific nucleic acid interactions.
- the spacers provide physical separation between the oligonucleotide and the solid surface and prevent interaction of the proteins with the support surface. This separation is important to ensure effective hybridization between the support-bound capture probe and the nucleic acid-protein fusion. In addition, the separation helps to minimize denaturation of the protein; the proteins are therefore able to adopt their native folded structures and remain functional.
- the spacer groups can be attached directly to the solid support surface, instead of to the capture probes.
- the spacer group can be attached to the amino groups on the surface.
- the bifunctional linker can then be attached to the other end of the spacer group.
- the capture probes may contain modifications that improve their hybridization properties and mismatch discrimination.
- they may contain base analogs, such as 5-propyne pyrimidines, intenucleotide analogues such as peptide nucleic acids (PNA), in which the bases are connected by peptide-like linkages, or carbohydrate modifications.
- PNA peptide nucleic acids
- the capture probes are suspended in an aqueous alkaline solution, then applied to defined positions of the support surface; the nucleophilic moieties at the termini of the capture probes react with the active sites of the bifunctional linkers to form covalent bonds.
- the density of the capture probes can be controlled by adjusting reaction time and oligo concentration. Alternatively, the density can be controlled by doping the solution with capture oligos that lack nucleophilic moieties or doping with simple organic compounds that possess amine functional groups.
- the capture probes can be applied using liquid deposition techniques, such as inkjet delivery, robotic quill delivery or spotting, and other similar deposition methods. They can also be applied using manual methods, such as pipetting.
- the feature sizes of the capture probes can range from one square micron (e.g., when robotic techniques are used) to one square millimeter (e.g., when a 0.2 microliter pipette is used).
- the result of the application of the capture probes is a defined, regular array of nucleic acid sequences.
- Blocking agents can also be selected to modify the surface energy, i.e., the hydrophobicity of the solid support surface.
- the hydrophobicity of the solid support surface is important because it affects the background signal level and the extent of unwanted interaction of the protein portion of a nucleic acid-protein fusion with the surface. Examples of blocking agents that modify hydrophobicity are methylamine, amino alcohols, and suitable amino-containing polyethylene oxide moieties.
- Non-covalent blocking agents can also be used to further minimize non-specific interactions between the fusion and the solid support (e.g., glass) surface.
- blocking agents include non-specific proteins such as BSA or casein, or similar commercially available blocking reagent formulations marketed for use with membranes.
- the capture probes arrayed on the surface of the solid support are then bound (for example, by hybridization) to nucleic acid-protein fusions, such as RNA-protein fusions.
- a solution containing the mixture of fusions is adjusted to an appropriate salt concentration, applied to the surface, and incubated at a suitable temperature to allow for efficient binding (for example, hybridization) between the capture probe and the target sequence.
- the solution may also contain surfactants such as TWEEN-20, TRITON X-100, or SDS (Sigma Chemical Co.) at concentrations of about 0.02% to about 1.0%; it may also include non-specific proteins, such as BSA.
- the experimental variables of salt concentration, temperature, and hybridization time are a function of the capture oligo design.
- a preferred range for the salt concentration is 25 mM to 2 M, with a concentration of about 750 mM being especially preferred.
- a preferred temperature range is from 5° C. to 70° C., with 30° C. being especially preferred.
- Preferred reaction times can be from 1 to 24 hours, with 3 hours being especially preferred.
- the variables for each experiment are determined empirically by standard methods.
- the hybridization step can be performed in a simple chamber device that constrains the liquid sample and prevents evaporation.
- the solution may also contain one or more components to suppress nuclease degradation of the RNA moiety.
- Preferred additions include (a) metal chelators (e.g., EDTA or EGTA) at concentrations of between 1-10 mM, (b) placental RNase inhibitor protein (Promega) at concentrations of between 0.1-1 Unit/ ⁇ l; and (c) Anti-RNase protein (Ambion) at concentrations of between 0.1-1 Unit/ ⁇ l.
- metal chelators e.g., EDTA or EGTA
- placental RNase inhibitor protein Promega
- Anti-RNase protein Ambion
- a separate strategy to specifically suppress 5′-exonuclease degradation involves capping the 5′-terminus of the fusion RNA with a binding molecule.
- the capping strategy may be used in conjunction with one or more of the components listed above.
- a native or analog (e.g., PNA) nucleic acid sequence complementary to the 5′-terminus of the fusion RNA is added to generate a stable duplex at the 5′-end.
- the complementary sequence is preferably between 10-50 bases in length, and most preferably about 20 bases in length.
- This added nucleic acid sequence may also contain pendant groove-binding, intercalating, or cross-linking moieties.
- native or analog nucleic acid sequences may be added that form stable intermolecular hairpin, tetraloop, or pseudoknot secondary structures with the 5′-terminus of the RNA. In the latter case, these nucleic acids are preferably about 20-100 bases in length, with about 35 bases being especially preferred.
- the mixture of nucleic acid-protein fusions should be free of un-fused nucleic acids.
- Un-fused nucleic acids that are complementary to the capture probes will compete with the fusions for binding and will limit the amount of a given protein that can be displayed on the solid support.
- at least 1% of the nucleic acid is fused to protein.
- hybridization tag sequences may include the same analogue units as are described above for the capture probes. In some cases, both the capture probe and the tag sequences can be modified so they hybridize preferentially with each other, thereby minimizing interference from the coding fusion sequences.
- the nucleic acid component of the fusion may be covalently linked to a part of the solid support, the linker, or the capture probe.
- covalently linked fusions provide particularly robust and versatile addressable arrays that may be used, for example, in the screening methods described herein.
- Covalently linked fusion arrays may be generated by any standard approach. According to one general technique, the fusions are addressed to specific locations on a solid surface via hybridization with corresponding capture probes, and a chemical cross-linking or attachment reaction is triggered to fix the location of the fusions on the solid support.
- One method to achieve such a covalent link involves functionalizing the DNA capture oligos during chemical synthesis with one or more pendant psoralen moieties, preferably positioned near adenosine bases.
- the surface is exposed to long-wavelength UV light (for example, at 350 nm). Light of this wavelength triggers a photoreaction between psoralen and an adjacent thymidine or uridine base in the duplex region, forming a cyclobutane linkage and permanently attaching the fusion to the solid support.
- psoralen itself i.e., not linked to a capture probe
- the psoralen molecule intercalates between bases in double-stranded regions.
- the intercalated psoralen cross-links with thymidine or uridine bases (intrastrand and interstrand) in a bifunctional mode, forming covalent links between the capture probe and the nucleic acid component of the fusion.
- Other reactive, cross-linking reagents may also be used in place of psoralen in combination with triggering conditions appropriate for those reagents.
- ribosome display particles such as those described in Gold et al., WO 93/03172, can be hybridized to the solid support to generate the protein array. Again, these particles are immobilized on the solid support through a hybridization reaction between the capture oligo and the protein-coding RNA.
- the addressable protein arrays of the present invention have many uses. For example, a library of proteins can be displayed on a support, such as a microchip. This microchip can then be used to identify previously unknown protein-protein interactions.
- a probe protein can be detectably labeled, for example, with a radioisotope, chromophore, fluorophore, or chemiluminescent species, then incubated with the microchip. After the excess probe protein is washed away, the chip surface is analyzed for signal from the label. Detection of a signal indicates interaction of the labeled protein with one or more unique members of the protein library.
- the identity of proteins that are able to bind to the probe protein can then be determined from the location of the spots on the chip that become labeled due to binding of the probe.
- the same approach can also be used to screen protein libraries for protein-ligand interactions and protein-nucleic acid interactions.
- SPR surface plasmon resonance
- the reactive moiety on the oligonucleotide capture probe is a thiol group (rather than an amino group) and the gold surface need not be functionalized to achieve capture probe attachment.
- Mass spectrometry especially, MALDI-TOF can also be used to analyze species bound to unique members of the protein library.
- protein arrays Another application of protein arrays is the rapid determination of proteins that are chemically modified through the action of modifying enzymes such as protein kinases, acyl transferases, and methyl transferases.
- modifying enzymes such as protein kinases, acyl transferases, and methyl transferases.
- the location and hence the identity of those proteins that are substrates for the modifying enzyme may be readily determined. Further localization of the modification sites can be achieved using ordered displays of fragments of these proteins.
- the protein arrays can also be used to identify the unknown protein targets of therapeutically active compounds.
- a therapeutic compound may be applied to a protein array derived from cellular RNA. Detection of the captured therapeutic compound, either through its bound label or directly (for example, by mass spectrometry or surface plasmon resonance) reveals the compound's binding partner or partners.
- arrays can also be used in the development of protein-based diagnostics. For example, a solid support containing a variety of proteins associated with various illnesses can be prepared. A single patient sample, which might contain one or more proteins whose interactions with the support-bound proteins would be indicative of certain illnesses, can then be contacted with the support.
- a single sample can be used to simultaneously detect the presence of several conditions, or to distinguish between conditions.
- addressable arrays may be used to quantify target molecules in a sample.
- addressable arrays of single chain antibodies or antibody mimics may be used for quantifying a target protein (or proteins) in a biological sample.
- the arrays can also be used in the emerging fields of proteomics and functional genomics.
- the specific fusions that are identified as binding specifically to a probe molecule can be removed from the support surface.
- the fusion is released by disrupting hybridization with the capture probe.
- the specified fusion is physically separated from the rest of the fusions, then treated with a denaturing agent, such as a chemical reagent or heat, to disrupt the base pairing with the capture oligo. The liberated fusion is then recovered from the solution.
- the entire capture probe can be detached.
- a light-sensitive linker can be used to attach the capture probe to the solid surface.
- a laser beam of the appropriate wavelength can be used to cleave the linker, thus releasing the desired fusion.
- the fusion can be specifically recovered and manipulated, for example, using PCR, and further characterized.
- Silane treated slides from Example 1 are immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF/10% pyridine for two hours, with gentle agitation. The slides are washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides are stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- phenylene 1,4-diisothiocyanate Aldrich Chemical Co.
- Oligonucleotides are chemically synthesized in the 3′ ⁇ 5′ direction by coupling standard phosphoramidite monomers with an automated DNA synthesizer. Typically, 500 angstrom controlled-pore glass supports are used at the 0.2 micromole scale. After the desired probe sequence has been assembled (using A, G, C, and T monomers), hexaethylene oxide phosphoramidite monomer (Glen Research) is added to the 5′ terminus. The coupling wait time is extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units are added in the same way. C-6 Amino phosphoramidite (Glen Research) is then added to the 5′ terminus; the coupling wait time is again extended to 15 minutes.
- Capture probe sequences are cleaved from the solid support and deprotected with ammonium hydroxide, concentrated to dryness, precipitated in ethanol, and purified by reverse-phase HPLC using an acetonitrile gradient in triethylammonium acetate buffer.
- the purified, amine-labeled capture probes from Example 3 are adjusted to a concentration of 500 micromolar in 100 mM sodium carbonate buffer (pH 9.0), and are applied to the derivatized glass surface from Example 2 at defined positions. For manual deposition, aliquots of 0.2 microliter each are applied with a pipetman. The array is incubated at room temperature in a moisture-saturated environment for at least two hours. The attachment reaction is terminated by immersing the glass surface in an aqueous 1% ammonia solution for five minutes with gentle agitation. The glass surface is then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. The array is then soaked in 1 M phosphate buffered saline (PBS) solution for 2 hours at room temperature, then rinsed again for 5 minutes in distilled water.
- PBS phosphate buffered saline
- the glass surface is then subjected to three 5-minute washes, using fresh portions of distilled water for each wash.
- the surface is soaked in 1 M phosphate buffered saline (PBS) solution for 2 hours, then washed again for 5 minutes with distilled water.
- PBS phosphate buffered saline
- the glass surface is immersed in a dilute, aqueous solution of a protein-containing blocking solution for several minutes, then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. Finally, the surface is air dried.
- RNA-protein fusions 50 microliters of a solution containing the RNA-protein fusions and consisting of 25 mM Tris-HCl (pH 8.0) and 100 mM potassium chloride are applied to the glass microchip surface in a chamber that can contain and seal the liquid.
- the solution is maintained at a specific temperature (determined by the capture oligo design) for at least three hours.
- non-hybridized RNA-protein fusions are removed by washing with 25 mM Tris-HCl (pH 8.0) and 50 mM potassium chloride for several minutes at the incubation temperature.
- the protein chip is subjected to two 15-minute washes, using a buffer that is more stringent and contains a lower salt concentration than the buffer used for the hybridization reaction.
- the glass slides were immersed in the hydrolyzed silane solution for 5 minutes with gentle agitation. Excess silane was removed by subjecting the slides to ten 5-minute washes, using fresh portions of 95% acetone / 5% water for each wash, with gentle agitation. The slides were then cured by heating at 110° C. for 20 minutes.
- the silane treated slides were immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF/10% pyridine for two hours, with gentle agitation. The slides were washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides were stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- phenylene 1,4-diisothiocyanate Aldrich Chemical Co.
- Capture oligos were then designed and synthesized by standard techniques.
- the RNA employed to make the FLAG epitope fusion (17 amino acids total) consisted of 5′-r(UAA UAC GAC UCA CUA UAG GGA CAA UUA CUA UUU ACA AUU ACA AUG GAC UAC AAG GAC GAU GAC GAU AAG GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG) (SEQ ID NO: 1).
- RNA employed to make the HA11 epitope fusion (20 amino acids total) consisted of 5′-r(UAA UAC GAC UCA CUA UAG GGA CAA UUA CUA UUU ACA AUU ACA AUG UAC CCC UAC GAC GUG CCC GAC UAC GCC GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG) (SEQ ID NO: 2).
- the following DNA linker which also contained the essential puromycin moiety at its 3′-end, was ligated to the 3′-terminus of the RNA message: 5′-d(AAAAAAAAAAAAAAAAAAAAAAACC). (SEQ ID NO: 3)
- oligonucleotides were prepared so that they could be attached to the chip surface at either the 3′- or 5′-terminus. Therefore, 16 capture probes were prepared comprising eight unique sequences. The following is a list of these capture probe sequences (5′ to 3′) (SEQ ID NOS: 4-11): CPt7: TGTAAATAGTAATTGTCCC CPtag: CTTCTCGAACTGGG CPau1: CCTGTAGGTGTCCAT CPau5: CAGGTAGAAGTCGGT CPflag: CATCGTCCTTGTAGTC CPha11: CGTCGTAGGGGTA CPirs: CCGCTCCTGATGTA CPkt3: TCGGGAGGCATTG.
- Oligonucleotide capture probes were chemically synthesized in the 3′ to 5′ direction by coupling standard phosphoramidite monomers using an automated DNA synthesizer (PE BioSystems Expedite 8909). Typically, 500 angstrom controlled-pore glass supports were used at the 0.2 micromole scale. In the case of 5′-attachment, after the desired probe sequence had been assembled (using A, G, C, and T monomers), four hexaethylene oxide phosphoramidite monomers (Glen Research) were added to the 5′-terminus. The coupling wait time was extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units were added in the same way.
- the oligos were adjusted to a concentration of 250 micromolar in 50 mM sodium carbonate buffer (pH 9.0) containing 10% glycerol.
- the oligos were then robotically applied (MicroGrid, BioRobotics) to the derivatized glass surface described above at defined positions in a 5 ⁇ 5 ⁇ 16 array pattern (384 spots) within a 20 ⁇ 20 mm area.
- the layout of these capture probes is shown schematically in FIG. 3.
- a 16-pin tool was used to transfer the liquid, producing 200 micron features with a pitch of 600 microns.
- Each sub-grid of 24 spots represented a single capture probe (i.e., 24 duplicate spots).
- the array was incubated at room temperature in a moisture-saturated environment for 12-18 hours.
- the attachment reaction was terminated by immersing the glass surface in an aqueous 1 % ammonia solution for five minutes with gentle agitation.
- the glass surface was then subjected to three 5-minute washes, using fresh portions of distilled water for each wash.
- the array was then soaked in a 10 ⁇ PBS (phosphate buffered saline) solution for 2 hours at room temperature, and then rinsed again for 5 minutes in distilled water.
- PBS phosphate buffered saline
- RNA-protein fusions between the peptides containing the FLAG and HA11 epitopes and their corresponding mRNAs were produced as generally described by Szostak et al., WO 98/31700; and Roberts and Szostak, Proc. Natl. Acad. Sci. USA 94:12297-12302, 1997.
- the polymerase chain reaction using Taq polymerase was used to amplify the sequences 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GAC TAC AAG GAC GAT GAC GAT GAC GAT AAG GGC GGC TGG TCC CAC CCC CAG TTC GAG AAG (SEQ ID NO: 12) and 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG TAC CCC TAC GAC GTG CCC GAC TAC GCC GGC GGC TGG TCC CAC CCC CAG TTC GAG AAG (SEQ ID NO: 13) for FLAG and HA11, respectively, using the oligonucleotide primers 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT (SEQ ID NO: 14) and 5′-AGCGGATGCCTTCTC
- RNA linker 5′-AAA AAA AAA AAA AAA AAA AAA AAA CC (SEQ ID NO: 3) containing a 5′ phosphate and a 3′ puromycin by T4 DNA ligase (Promega) in the presence of an 80:20 mixture of the following two DNA splints:
- RNA-DNA chimera was purified by binding to Immobilized NeutrAvidin (Pierce), washing to remove unligated material, and eluting by displacement using the sequence 5′-GCATCCGCTAAAAAAAAAAGTTGGTCGTTGC (SEQ ID NO: 18).
- RNA-peptide fusions were then purified by oligo dT affinity chromatography (Pharmacia), quantitated by scintillation counting of the incorporated vs. added 35 S methionine (Amersham), and concentrated to a low volume via membrane filtration (MicroCon).
- the FLAG and HA11-fusion chip was exposed to a phosphorimage screen (Molecular Dynamics) for 60 hours by direct contact between the screen and the chip. This allowed identification of the areas that contained hybridized fusions, since the peptides contained a 35 S methionine radiolabel which was detectable by the phosphor storage screen. As shown in FIG. 4, analysis of the phosphorimage revealed that the fusions had successfully hybridized to their respective capture probes targeting specific areas of the RNA message (i.e.,.CPflag and CPha11).
- the four non-sense capture probes which were not compelementary to any region of the FLAG or HA11 RNA, did not give any appreciable signal (i.e., CPau1, CPau5, CPirs, CPkt3).
- the positive control capture probe CPtag produced the expected signal, but the corresponding positive control capture probe CPt7 did not, likely due to degradation (e.g., exonuclease contamination) of the 5′-region of the targeted RNA.
- a duplicate chip was probed with a monoclonal antibody that recognized the HA11 epitope. All of the following steps were performed at 4° C. Nonspecific sites were first blocked with a solution containing 1 ⁇ PBS (phosphate buffered saline)+1% BSA (bovine serum albumin, RNAse free grade, Ambion)+0.02% Tween-20 for 1 hour under a coverslip. The blocking solution was removed and 50 microliters of HA.11 monoclonal antibody (100:1 dilution, Berkeley Antibody Co.) in 1 ⁇ PBS+0.02% Tween-20 was applied to the chip under a coverslip.
- 1 ⁇ PBS phosphate buffered saline
- BSA bovine serum albumin, RNAse free grade, Ambion
- the chip was subsequently analyzed at 10 micron pixel resolution with a confocal laser scanner (ScanArray 3000, General Scanning) using preset excitation and emission wavelengths tuned to the Cy3 fluorophore.
- the resulting fluorimage was in accord with the phosphorimage and demonstrated that the HA11 peptide, which was covalently linked to its RNA message and fixed to the chip surface, was functional and was available to interact with its binding partner (the HA11 monoclonal antibody).
- the HA11 monoclonal antibody was specific for its own epitope.
- the 3′-attachment capture probes generally provided a better signal than the 5′-attachment capture probes. Without being bound to a particular theory, this may reflect the greater accessibility of the epitope when it is oriented away from the chip surface.
- an exemplary Myc fusion chip was also generated as follows.
- the silane treated slides were immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF /10% pyridine for two hours, with gentle agitation. The slides were washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides were stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- phenylene 1,4-diisothiocyanate Aldrich Chemical Co.
- the capture oligos were synthesized based on the Myc sequence.
- the RNA employed to make the c-myc fusion (33 amino acids total) consisted of the following sequence:
- Oligonucleotide capture probes were chemically synthesized in the 3′ to 5′ direction by coupling standard phosphoramidite monomers with an automated DNA synthesizer (PE BioSystems Expedite 8909). Typically, 500 angstrom controlled-pore glass supports were used at the 0.2 micromole scale. After the desired probe sequence had been assembled (using A, G, C, and T monomers), hexaethylene oxide phosphoramidite monomer (Glen Research) was added to the 5′-terminus. The coupling wait time was extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units were added in the same way.
- the oligos were adjusted to a concentration of 500 micromolar in 100 mM sodium carbonate buffer (pH 9.0) and were applied to the derivatized glass surface at defined positions in a 6 ⁇ 6 array pattern (36 spots) within a 20 ⁇ 20 nm area (as shown in FIG. 6).
- CP01 was applied to locations A1, B1, C1 and A4, B4, C4.
- CP33 was applied to locations D1, E1, F1 and D4, E4, F4.
- CP80 was applied to locations A2, B2, C2 and A5, B5, C5.
- CP125 was applied to locations D2, E2, F2 and D5, E5, F5.
- Cpmm was applied to locations A3, B3, C3 and A6, B6, C6.
- Cpns was applied to locations D3, E3, F3 and D6, E6, F6.
- the array was incubated at room temperature in a moisture-saturated environment for 12-18 hours.
- the attachment reaction was terminated by immersing the glass surface in an aqueous 1 % ammonia solution for five minutes with gentle agitation.
- the glass surface was then subjected to three 5-minute washes, using fresh portions of distilled water for each wash.
- the array was then soaked in a 10 ⁇ PBS (phosphate buffered saline) solution for 2 hours at room temperature, and then rinsed again for 5 minutes in distilled water.
- PBS phosphate buffered saline
- RNA-protein fusions between a 33 amino acid peptide containing the c-myc epitope and its mRNA were produced as described by Szostak et al., WO 98/31700; and Roberts and Szostak, Proc. Natl. Acad. Sci. USA 94:12297-12302, 1997.
- the polymerase chain reaction using Taq polymerase was used to amplify the sequence 5′-AGC GCA AGA GTT ACG CAG CTG TTC CAG TTT GTG TTT CAG CTG TTC ACG ACG TTT ACG CAG CAG GTC TTC AGA GAT CAG TTT CTG TTC TTC AGC CAT (SEQ ID NO: 26) using oligonucleotide primers 5′-AGC GCA AGA GTT ACG CAG CTG (SEQ ID NO: 27) and 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GCT GAA GAA CAG AAA CT (SEQ ID NO: 28).
- RNA linker 5′-AAA AAA AAA AAA AAA AAA AAA AAA CC (SEQ ID NO: 3) containing a 5′ phosphate and a 3′ puromycin by T4 DNA ligase (Promega) in the presence of a DNA splint with the sequence TTT TTT TTT TAG CGC AAG A (SEQ ID NO: 29).
- RNA-DNA chimera was purified by denaturing polyacrylamide gel electrophoresis (6% acrylamide). Translation was performed in rabbit reticulocyte lysate (Ambion) according to the manufacturer's instructions except that KCl (500 mM) was added after 30 minutes to promote the formation of the puromycin-peptide bond.
- the RNA-peptide fusion was purified by oligo dT affinity chromatography (Pharmacia), quantitated by scintillation counting of the incorporated vs. added 35 S methionine (Amersham), and dried to a pellet. 2.5 pmol of the c-myc fusion was produced.
- the dry myc-fusion pellet was taken up with 20 microliters of 5 ⁇ SSC (saline sodium citrate)+0.02% SDS, mixed, and then briefly centrifuged.
- the solution was applied to the slide described above, a coverslip was placed on top, and the slide was placed in a moisture-saturated chamber at room temperature. After 18 hours the coverslip was removed, and the slide was washed sequentially with stirred 500 mL portions of 5 ⁇ SSC+0.02% SDS, 2.5 ⁇ SSC+0.01% SSC, 2.5 ⁇ SSC, and 1.25 ⁇ SSC for 5 minutes each. After removal of liquid the slide was allowed to briefly air-dry.
- the chip was subsequently analyzed at 10 micron pixel resolution with a confocal laser scanner (ScanArray 3000, General Scanning) using preset excitation and emission wavelengths tuned to the Cy3 fluorophore.
- the resulting fluorimage was in accord with the phosphorimage and demonstrated that the myc peptide, which was covalently linked to its RNA message and fixed to the chip surface, was functional and was available to interact with its binding partner (the monoclonal antibody).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Materials Engineering (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Geochemistry & Mineralogy (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Composite Materials (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Disclosed herein are arrays of nucleic acid-protein fusions which are immobilized to a solid surface through capture probes which include a non-nucleosidic spacer group and an oligonucleotide sequence to which the fusion (such as an RNA-protein fusion) is bound. Also disclosed herein are solid supports on which these arrays are immobilized as well as methods for their preparation and use (for example, for screening for protein-compound interactions such as protein-therapeutic compound interactions).
Description
- This application is a divisional of U.S. Ser. No. 09/282,734, filed Mar. 31, 1999, which claims the benefit of U.S. provisional application, U.S. Ser. No. 60/080,686, filed Apr. 3, 1998, hereby incorporated by reference.
- The invention relates to fixed arrays of nucleic acid-protein fusions and, in particular, RNA-protein fusions, on solid supports.
- Certain macromolecules, such as proteins, are known to interact specifically with other molecules based on the three-dimensional shapes and electronic distributions of those molecules. For example, proteins interact selectively with other proteins, with nucleic acids, and with small-molecules. Modem pharmaceutical research relies on the study of these interactions; the development of new drugs depends on the discovery of compounds that bind specifically to biologically important molecules.
- The discovery of a single drug candidate can require the screening of thousands of compounds. It is therefore important to be able to screen large numbers of compounds rapidly and efficiently. One method for screening a large number of compounds is to fix possible binding partners, such as proteins, to a solid support.
- It is difficult to prepare arrays of isolated proteins on solid supports, however, for a variety of reasons. First of all, proteins cannot always be easily attached to the planar surfaces traditionally used to make other fixed arrays, such as nucleic acid microchips. More importantly, because proteins can interact with the functional groups on the surfaces of these supports, the proximity of the protein to the surface can lead to disruption of the protein structure.
- In general, the invention features a solid support including an array of immobilized capture probes; each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion is bound (for example, hybridized or covalently bound). In preferred embodiments, the nucleic acid-protein fusion is an RNA-protein fusion, and the protein component is encoded by the nucleic acid (for example, the RNA). The spacer group can include a polyalkylene oxide, for example, polyethylene oxide. A preferred spacer group includes hexaethylene oxide. The capture probe may also include a photocleavable linker.
- The oligonucleotide sequence can include a modified base, such as 5-propyne pyrimidine. It can also include an internucleotide analog (such as 3′-phosphoramidate) or a carbohydrate modification (such as a 2′-O-methyl group). The nucleic acid-protein fusion can include a hybridization tag sequence. The hybridization tag sequence can also include a modified base, an intemucleotide analog, or a carbohydrate modification.
- In a preferred embodiment, the capture probe further includes a reactive moiety (for example, a nucleophilic group), such as a primary amino group. In another preferred embodiment, the nucleic acid-protein fusion is covalently linked to the capture probe (for example, by photo-crosslinking); in one preferred approach, this is accomplished by including one or more psoralen moieties in the capture probe or in the capture probe-fusion hybridization reaction mixture. A preferred solid support is a glass or silica-based chip.
- In a related aspect, the invention features a solid support including an array of immobilized capture probes; each of the capture probes is attached to the surface of the solid support through a non-nucleosidic spacer group, and each of the capture probes includes an oligonucleotide sequence to which a nucleic acid-protein fusion (for example, an RNA-protein fusion) is bound (for example, hybridized or covalently bound).
- In another related aspect, the invention features a solid support including an array of immobilized capture probes; each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a ribosome display particle is bound (for example, hybridized or covalently bound).
- In yet another related aspect, the invention features a method for preparing a solid support. The method includes the steps of: (a) preparing a capture probe by linking a spacer group to an oligonucleotide sequence; (b) attaching the capture probe to the solid support; and (c) binding (for example, hybridizing or covalently binding) a nucleic acid-protein fusion (for example, an RNA-protein fusion) to the capture probe.
- The invention also features a second general method for preparing a solid support. This method includes the steps of: (a) attaching a spacer group to a surface of the solid support; (b) attaching a bifunctional linker to the spacer group; (c) attaching a capture probe to the bifunctional linker; and (d) binding (for example, hybridizing or covalently binding) a nucleic acid-protein fusion (for example, an RNA-protein fusion) to the capture probe.
- In a second aspect, the invention features a method for detecting an interaction between a protein and a compound. The method includes the steps of: (a) providing a solid support including an array of immobilized capture probes, where each of the capture probes includes a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion is bound (for example, hybridized or covalently bound); (b) contacting the solid support with a candidate compound under conditions which allow an interaction between the protein portion of the nucleic acid-protein fusion and the compound; and (c) analyzing the solid support for the presence of the compound as an indication of an interaction between the protein and the compound.
- Alternatively, the invention features another method for detecting an interaction between a protein and a compound; this method involves the steps of: (a) providing a population of nucleic acid-protein fusions; (b) contacting the population of nucleic acid-protein fusions with a candidate compound under conditions which allow an interaction between the protein portion of the nucleic acid-protein fusion and the compound; (c) contacting the product of step (b) with a solid support that includes an array of immobilized capture probes, each of the capture probes including a non-nucleosidic spacer group and an oligonucleotide sequence to which a nucleic acid-protein fusion binds (for example, hybridizes or covalently binds); and (d) analyzing the solid support for the presence of the compound as an indication of an interaction between the protein and the compound.
- In a preferred embodiment of each of the above methods, the nucleic acid-protein fusion is an RNA-protein fusion. In another preferred embodiment, the compound is labeled. Compounds that can be screened using these methods include, without limitation, proteins, drugs, therapeutics, enzymes, and nucleic acids.
- In a third aspect, the invention features an array (for example, an addressable array) of nucleic acid-protein fusions including at least 102 different fusions/cm2. Preferably, the nucleic acid-protein fusions are RNA-protein fusions, and the array includes at least 104 different fusions/cm2.
- In a related aspect, the invention features a method for generating an addressable array of molecules. The method involves: (a) providing a solid support on which an array of nucleic acid molecules is immobilized; (b) contacting the solid support with a population of addressable molecules; and (c) allowing the addressable molecules to orient themselves on the solid support by sequence-dependent recognition and binding of the immobilized nucleic acid molecules.
- In preferred embodiments of this method, the addressable array of molecules is an array of nucleic acid-protein fusions (for example, an array of RNA-protein fusions); the addressable molecules orient themselves on the solid support by base pairing (for example, hybridization) with the immobilized nucleic acid molecules; the solid support is a glass or silica-based chip; and the nucleic acid molecules immobilized on the solid support are capture probes, each including a non-nucleosidic spacer group and an oligonucleotide sequence to which the addressable molecule binds.
- As used herein, by an “array” is meant a fixed pattern of immobilized objects on a solid surface or membrane. Typically, the array is made up of nucleic acid-protein fusion molecules (for example, RNA-protein fusion molecules) bound to capture nucleic acid sequences which themselves are immobilized on the solid surface or membrane. The array preferably includes at least 102, more preferably at least 103, and most preferably at least 104 different fusions, and these fusions are preferably arrayed on a 125×80 mm, and more preferably on a 10×10 mm, surface. By an “addressable array” is meant that the locations, or addresses, on the solid support of the members of the array (for example, the nucleic acid-protein fusions) are known; the members of the array are referred to as “addressable molecules” and are utilized in methods for screening for subsequent molecular interactions (for example, for screening for interactions between the addressable nucleic acid-protein fusions and candidate therapeutics).
- By “nucleic acid-protein fusion” is meant a nucleic acid covalently bonded to a protein. By “nucleic acid” is meant any two or more covalently bonded nucleotides or nucleotide analogs or derivatives. As used herein, this term includes, without limitation, DNA, RNA, and PNA. By “protein” is meant any two or more amino acids, or amino acid analogs or derivatives, joined by peptide or peptoid bond(s), regardless of length or post-translational modification. As used herein, this term includes, without limitation, proteins, peptides, and polypeptides.
- By “hybridization tag” is meant a non-coding oligonucleotide sequence that differs sufficiently in sequence from other nucleic acid sequences in a given population or reaction mixture that significant cross-hybridization does not occur. When multiple hybridization tags are utilized in a single reaction mixture, these tags also preferably differ in sequence from one another such that each has a unique binding partner under the conditions employed.
- By a “population” is meant more than one molecule.
- By a “solid support” is meant any solid surface including, without limitation, any chip (for example, silica-based, glass, or gold chip), glass slide, membrane, bead, solid particle (for example, agarose, sepharose, or magnetic bead), column (or column material), test tube, or microtiter dish.
- FIG. 1 is a drawing showing the silylation of a glass surface, the derivatization of the resulting amino groups, and the attachment of a capture probe to the modified surface.
- FIG. 2 is a drawing illustrating a capture probe containing a non-nucleosidic spacer group and a reactive moiety.
- FIG. 3 is a schematic diagram of the layout of the FLAG and HA11 fusion chip capture probes utilized in FIGS. 4 and 5. In this Figure, t7, tag, au1, au5, flag, ha1, irs, and kt3 represent the capture probes CPt7 (positive control), CPtag (positive control), CPau1 (negative control), CPau5 (negative control), CPflag, CPha11, CPirs (negative control), and CPkt3 (negative control), respectively.
- FIG. 4 is a phosphorimage demonstrating hybridization of nucleic acid-protein fusions (FLAG and HA11) to capture probes immobilized on a chip.
- FIG. 5 is a fluorimage demonstrating hybridization of nucleic acid-protein fusions (FLAG and HA11) to capture probes immobilized on a chip and subsequent recognition with anti-HA11 monoclonal antibodies.
- FIG. 6 is a schematic diagram of the layout of the Myc fusion chip capture probes utilized in FIGS. 7 and 8. In this Figure, capture probes CP01, CP33, CP80, CP125, CPmm, and CPns (described herein) were arranged on the chip as follows: CP01 at locations A1, B1, C1, A4, B4, and C4; CP33 at locations D1, E1, F1, D4, E4, and F4; CP80 at locations A2, B2, C2, A5, B5, and C5; CP125 at locations D2, E2, F2, D5, E5, and F5; CPmm at locations A3, B3, C3, A6, B6, and C6; and CPns at locations D3, E3, F3, D6, E6, and F6.
- FIG. 7 is a phosphorimage demonstrating hybridization of nucleic acid-protein fusions (Myc) to capture probes immobilized on a chip.
- FIG. 8 is a fluorimage demonstrating hybridization of nucleic acid-protein fusions (Myc) to capture probes immobilized on a chip and subsequent recognition with anti-Myc monoclonal antibodies.
- The invention features support-based, addressable arrays of proteins, and methods for preparing and using these arrays. The arrays are prepared by fixing oligonucleotide sequences, the capture probes (or capture oligos), to a support in a defined array. The capture probes are then used to bind nucleic acid-protein fusions, such as RNA-protein fusions. Such binding may occur through base pairing (for example, through Watson-Crick base pairing, pseudo Watson-Crick base pairing involving modified bases, or Hoogsteen base pairing) between the nucleic acid component of the fusion and a complementary capture probe, or may occur through any other type of sequence-dependent recognition and binding of the capture probe (including, without limitation, polyamide-mediated nucleic acid groove binding or specific binding by nucleic acid-binding proteins such as transcription factors). The result of the binding interactions between the fusions and the capture probes is a defined, addressable array of proteins attached to a solid support.
- A variety of materials can be used as the solid support. Examples of such materials include polymers (e.g., plastics), aminated surfaces, gold coated surfaces, nylon membranes, polyacrylamide pads deposited on solid surfaces, silicon, silicon-glass (e.g., microchips), silicon wafers, and glass (e.g., microscope slides). Microchips, and particularly glass microchips, represent a preferred solid support surface.
- If the surface is not already aminated, it can be modified to provide a layer of amino groups. For example, a glass microscope slide can be treated with a silylating agent such as trialkoxyaminosilane to provide a surface of primary amino groups that exists as a monolayer or 3-8 molecular layers. This reaction is illustrated in FIG. 1. The silane-treated surface is then derivatized with a homobifunctional or heterobifunctional linker that permits the attachment of oligonucleotides at discrete positions. Phenylene 1,4-diisothiocyanate is a useful homobifunctional linker; amino-surfaces derivatized with this reagent have isothiocyanate functionalities that are available to covalently react with the primary amino groups on the termini of oligonucleotides to form stable thiourea bonds, as shown in FIG. 1.
- The capture probes, i.e., the oligonucleotide sequences that are to be attached to the surface, are selected from the reverse-complements of the nucleic acid components of the nucleic acid-protein fusions (the targets). Capture probes preferably have between 5 and 30 nucleotide units, and more preferably have about 20 nucleotide units. Considerations for the selection of the exact sequence for a particular capture probe include melting temperature (Tm), interference from competing target sequences, and potential secondary structure in the target sequence. Ideally, each unique capture probe has the same Tm, i.e., they are isoenergetic, so a single hybridization and washing temperature can be used successfully for all capture-target pairs. Commercially available computer programs (e.g., Oligo 4.0) can be used to help identify sets of capture probes with similar thermodynamic properties based on nearest neighbor treatments.
- The capture probes are modified before they are attached to the surface. One or more non-nucleosidic spacers, such as polyethylene oxide, are added to the terminus of the oligo. Preferably, 1-20 spacers and, most preferably, 4 spacers are utilized. These spacers may be added to either the 5′ or preferably the 3′ end of the oligonucleotide. A nucleophilic moiety is then attached to the spacer group. The result is a derivatized capture probe, as shown in FIG. 2. A preferred spacer monomer includes hexaethylene oxide.
- Non-nucleosidic spacers are preferred over nucleosidic spacers, such as poly-T, because non-nucleosidic spacers have greater flexibility. In addition, their physical properties can be tailored relatively easily, and it is possible to minimize specific and non-specific nucleic acid interactions.
- The spacers provide physical separation between the oligonucleotide and the solid surface and prevent interaction of the proteins with the support surface. This separation is important to ensure effective hybridization between the support-bound capture probe and the nucleic acid-protein fusion. In addition, the separation helps to minimize denaturation of the protein; the proteins are therefore able to adopt their native folded structures and remain functional.
- Alternatively, the spacer groups can be attached directly to the solid support surface, instead of to the capture probes. For example, the spacer group can be attached to the amino groups on the surface. The bifunctional linker can then be attached to the other end of the spacer group.
- In addition to spacer groups, the capture probes may contain modifications that improve their hybridization properties and mismatch discrimination. For example, they may contain base analogs, such as 5-propyne pyrimidines, intenucleotide analogues such as peptide nucleic acids (PNA), in which the bases are connected by peptide-like linkages, or carbohydrate modifications.
- The capture probes are suspended in an aqueous alkaline solution, then applied to defined positions of the support surface; the nucleophilic moieties at the termini of the capture probes react with the active sites of the bifunctional linkers to form covalent bonds. The density of the capture probes can be controlled by adjusting reaction time and oligo concentration. Alternatively, the density can be controlled by doping the solution with capture oligos that lack nucleophilic moieties or doping with simple organic compounds that possess amine functional groups.
- The capture probes can be applied using liquid deposition techniques, such as inkjet delivery, robotic quill delivery or spotting, and other similar deposition methods. They can also be applied using manual methods, such as pipetting. The feature sizes of the capture probes can range from one square micron (e.g., when robotic techniques are used) to one square millimeter (e.g., when a 0.2 microliter pipette is used). The result of the application of the capture probes is a defined, regular array of nucleic acid sequences.
- After a sufficient reaction time, the excess capture probe is washed away, and the remaining unreacted isothiocyanate groups are blocked off. Dilute ammonia can be used as the blocking agent, resulting in a surface of phenyl thiourea groups. Blocking agents can also be selected to modify the surface energy, i.e., the hydrophobicity of the solid support surface. The hydrophobicity of the solid support surface is important because it affects the background signal level and the extent of unwanted interaction of the protein portion of a nucleic acid-protein fusion with the surface. Examples of blocking agents that modify hydrophobicity are methylamine, amino alcohols, and suitable amino-containing polyethylene oxide moieties.
- Non-covalent blocking agents can also be used to further minimize non-specific interactions between the fusion and the solid support (e.g., glass) surface. Examples of such blocking agents include non-specific proteins such as BSA or casein, or similar commercially available blocking reagent formulations marketed for use with membranes.
- The capture probes arrayed on the surface of the solid support are then bound (for example, by hybridization) to nucleic acid-protein fusions, such as RNA-protein fusions. A solution containing the mixture of fusions is adjusted to an appropriate salt concentration, applied to the surface, and incubated at a suitable temperature to allow for efficient binding (for example, hybridization) between the capture probe and the target sequence. The solution may also contain surfactants such as TWEEN-20, TRITON X-100, or SDS (Sigma Chemical Co.) at concentrations of about 0.02% to about 1.0%; it may also include non-specific proteins, such as BSA.
- The experimental variables of salt concentration, temperature, and hybridization time are a function of the capture oligo design. A preferred range for the salt concentration is 25 mM to 2 M, with a concentration of about 750 mM being especially preferred. A preferred temperature range is from 5° C. to 70° C., with 30° C. being especially preferred. Preferred reaction times can be from 1 to 24 hours, with 3 hours being especially preferred. The variables for each experiment are determined empirically by standard methods. The hybridization step can be performed in a simple chamber device that constrains the liquid sample and prevents evaporation.
- When RNA-protein fusions are utilized as addressable arrays, the solution may also contain one or more components to suppress nuclease degradation of the RNA moiety. Preferred additions include (a) metal chelators (e.g., EDTA or EGTA) at concentrations of between 1-10 mM, (b) placental RNase inhibitor protein (Promega) at concentrations of between 0.1-1 Unit/μl; and (c) Anti-RNase protein (Ambion) at concentrations of between 0.1-1 Unit/μl. A separate strategy to specifically suppress 5′-exonuclease degradation involves capping the 5′-terminus of the fusion RNA with a binding molecule. The capping strategy may be used in conjunction with one or more of the components listed above. In one particular capping approach, a native or analog (e.g., PNA) nucleic acid sequence complementary to the 5′-terminus of the fusion RNA is added to generate a stable duplex at the 5′-end. The complementary sequence is preferably between 10-50 bases in length, and most preferably about 20 bases in length. This added nucleic acid sequence may also contain pendant groove-binding, intercalating, or cross-linking moieties. Alternatively, native or analog nucleic acid sequences may be added that form stable intermolecular hairpin, tetraloop, or pseudoknot secondary structures with the 5′-terminus of the RNA. In the latter case, these nucleic acids are preferably about 20-100 bases in length, with about 35 bases being especially preferred.
- To the extent possible, the mixture of nucleic acid-protein fusions should be free of un-fused nucleic acids. Un-fused nucleic acids that are complementary to the capture probes will compete with the fusions for binding and will limit the amount of a given protein that can be displayed on the solid support. Preferably, at least 1% of the nucleic acid (for example, the RNA message) is fused to protein.
- Unique non-coding regions can be incorporated into the nucleic acid component of the fusion for the specific purpose of being “captured” by the capture probe; these non-coding regions are referred to as “hybridization tag sequences.” The hybridization tag sequences may include the same analogue units as are described above for the capture probes. In some cases, both the capture probe and the tag sequences can be modified so they hybridize preferentially with each other, thereby minimizing interference from the coding fusion sequences.
- Upon completion of the binding step, unbound nucleic acid-protein fusion is washed away with a buffer that has a higher stringency and a lower salt concentration than that used for the hybridization step. Again, the optimal buffer composition is determined empirically by standard methods. What remains upon completion of washing is an addressable array of proteins on the solid surface, attached via sequence-dependent recognition between the nucleic acid component of the fusion and the surface-bound capture oligo. The position of each protein is defined, because each fusion corresponds to the complementary capture probe.
- In addition, if desired, the nucleic acid component of the fusion may be covalently linked to a part of the solid support, the linker, or the capture probe. Such covalently linked fusions provide particularly robust and versatile addressable arrays that may be used, for example, in the screening methods described herein. Covalently linked fusion arrays may be generated by any standard approach. According to one general technique, the fusions are addressed to specific locations on a solid surface via hybridization with corresponding capture probes, and a chemical cross-linking or attachment reaction is triggered to fix the location of the fusions on the solid support. One method to achieve such a covalent link involves functionalizing the DNA capture oligos during chemical synthesis with one or more pendant psoralen moieties, preferably positioned near adenosine bases. After hybridizing the nucleic acid-protein fusion (for example, the RNA-protein fusion) to the support-bound capture oligos, the surface is exposed to long-wavelength UV light (for example, at 350 nm). Light of this wavelength triggers a photoreaction between psoralen and an adjacent thymidine or uridine base in the duplex region, forming a cyclobutane linkage and permanently attaching the fusion to the solid support. Alternatively, psoralen itself (i.e., not linked to a capture probe) may be included in the hybridization solution or in a subsequent separate solution. The psoralen molecule intercalates between bases in double-stranded regions. Upon irradiation with long-wavelength UV light, the intercalated psoralen cross-links with thymidine or uridine bases (intrastrand and interstrand) in a bifunctional mode, forming covalent links between the capture probe and the nucleic acid component of the fusion. Other reactive, cross-linking reagents may also be used in place of psoralen in combination with triggering conditions appropriate for those reagents.
- Ordered, addressable arrays of peptide fragments can also be prepared. To prepare these arrays, the fusion library is generated from short synthetic DNA sequences or fragments of cDNAs or genomic DNAs. In another variation, ribosome display particles, such as those described in Gold et al., WO 93/03172, can be hybridized to the solid support to generate the protein array. Again, these particles are immobilized on the solid support through a hybridization reaction between the capture oligo and the protein-coding RNA.
- Use
- The addressable protein arrays of the present invention have many uses. For example, a library of proteins can be displayed on a support, such as a microchip. This microchip can then be used to identify previously unknown protein-protein interactions. A probe protein can be detectably labeled, for example, with a radioisotope, chromophore, fluorophore, or chemiluminescent species, then incubated with the microchip. After the excess probe protein is washed away, the chip surface is analyzed for signal from the label. Detection of a signal indicates interaction of the labeled protein with one or more unique members of the protein library. The identity of proteins that are able to bind to the probe protein can then be determined from the location of the spots on the chip that become labeled due to binding of the probe. The same approach can also be used to screen protein libraries for protein-ligand interactions and protein-nucleic acid interactions.
- Other methods can be used to detect protein-protein, protein-ligand, or protein-nucleic acid interactions. For example, when the solid surface used to form the protein array is a gold layer, surface plasmon resonance (SPR) can be used to detect mass changes at the surface. When gold surfaces are employed, the reactive moiety on the oligonucleotide capture probe is a thiol group (rather than an amino group) and the gold surface need not be functionalized to achieve capture probe attachment. Mass spectrometry (especially, MALDI-TOF) can also be used to analyze species bound to unique members of the protein library.
- Another application of protein arrays is the rapid determination of proteins that are chemically modified through the action of modifying enzymes such as protein kinases, acyl transferases, and methyl transferases. By incubating the protein array with the enzyme of interest and a radioactively labeled substrate, followed by washing and autoradiography, the location and hence the identity of those proteins that are substrates for the modifying enzyme may be readily determined. Further localization of the modification sites can be achieved using ordered displays of fragments of these proteins.
- The protein arrays can also be used to identify the unknown protein targets of therapeutically active compounds. For example, a therapeutic compound may be applied to a protein array derived from cellular RNA. Detection of the captured therapeutic compound, either through its bound label or directly (for example, by mass spectrometry or surface plasmon resonance) reveals the compound's binding partner or partners. In addition, arrays can also be used in the development of protein-based diagnostics. For example, a solid support containing a variety of proteins associated with various illnesses can be prepared. A single patient sample, which might contain one or more proteins whose interactions with the support-bound proteins would be indicative of certain illnesses, can then be contacted with the support. Thus, a single sample can be used to simultaneously detect the presence of several conditions, or to distinguish between conditions. Alternatively, addressable arrays may be used to quantify target molecules in a sample. In one particular example, addressable arrays of single chain antibodies or antibody mimics may be used for quantifying a target protein (or proteins) in a biological sample. The arrays can also be used in the emerging fields of proteomics and functional genomics.
- The specific fusions that are identified as binding specifically to a probe molecule can be removed from the support surface. In one method, the fusion is released by disrupting hybridization with the capture probe. In one particular approach, the specified fusion is physically separated from the rest of the fusions, then treated with a denaturing agent, such as a chemical reagent or heat, to disrupt the base pairing with the capture oligo. The liberated fusion is then recovered from the solution.
- Alternatively, the entire capture probe can be detached. During solid support preparation, a light-sensitive linker can be used to attach the capture probe to the solid surface. Following identification of the active fusion, a laser beam of the appropriate wavelength can be used to cleave the linker, thus releasing the desired fusion. Following release from the surface by any of the above methods, the fusion can be specifically recovered and manipulated, for example, using PCR, and further characterized.
- There now follow particular examples of the preparation of protein arrays according to the invention. These examples are provided for the purpose of illustrating the invention, and should not be construed as limiting.
- Silylation of a Glass Surface
- Select grade, low-iron content, pre-cleaned 1×3 inch glass microscope slides (VWR Scientific) are prepared by heating with 1 M hydrochloric or nitric acid for 30 minutes at 70° C. The slides are then subjected to three 5-minutes washes, using fresh distilled water for each wash. A 1% solution of aminopropyltrimethoxysilane (Gelest, Inc.) in 95% acetone/5% water is prepared and allowed to hydrolyze for at least five minutes. The glass slides are immersed in the hydrolyzed silane solution for 2-20 minutes with gentle agitation. Excess silane is removed by subjecting the slides to ten 5-minute washes, using fresh portions of 95% acetone/5% water for each wash, using gentle agitation. The slides are then cured by heating at 110° C. for 20-45 minutes.
- Derivatization with a Homobifunctional Linker
- Silane treated slides from Example 1 are immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF/10% pyridine for two hours, with gentle agitation. The slides are washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides are stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- Synthesis of Capture Probes
- Oligonucleotides are chemically synthesized in the 3′→5′ direction by coupling standard phosphoramidite monomers with an automated DNA synthesizer. Typically, 500 angstrom controlled-pore glass supports are used at the 0.2 micromole scale. After the desired probe sequence has been assembled (using A, G, C, and T monomers), hexaethylene oxide phosphoramidite monomer (Glen Research) is added to the 5′ terminus. The coupling wait time is extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units are added in the same way. C-6 Amino phosphoramidite (Glen Research) is then added to the 5′ terminus; the coupling wait time is again extended to 15 minutes. The acetic anhydride capping step and the final acidic detritylation step are eliminated. Capture probe sequences are cleaved from the solid support and deprotected with ammonium hydroxide, concentrated to dryness, precipitated in ethanol, and purified by reverse-phase HPLC using an acetonitrile gradient in triethylammonium acetate buffer.
- Attachment of Capture Probes
- The purified, amine-labeled capture probes from Example 3 are adjusted to a concentration of 500 micromolar in 100 mM sodium carbonate buffer (pH 9.0), and are applied to the derivatized glass surface from Example 2 at defined positions. For manual deposition, aliquots of 0.2 microliter each are applied with a pipetman. The array is incubated at room temperature in a moisture-saturated environment for at least two hours. The attachment reaction is terminated by immersing the glass surface in an aqueous 1% ammonia solution for five minutes with gentle agitation. The glass surface is then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. The array is then soaked in 1 M phosphate buffered saline (PBS) solution for 2 hours at room temperature, then rinsed again for 5 minutes in distilled water.
- Surface Modification
- The ammonia solution from Example 4 is replaced with a 1-5% aqueous solution of a different primary amine-containing molecule. A small amount (10%) of methanol or acetonitrile cosolvent is added, if necessary.
- The glass surface is then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. The surface is soaked in 1 M phosphate buffered saline (PBS) solution for 2 hours, then washed again for 5 minutes with distilled water. The glass surface is immersed in a dilute, aqueous solution of a protein-containing blocking solution for several minutes, then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. Finally, the surface is air dried.
- Fusion Hybridization
- 50 microliters of a solution containing the RNA-protein fusions and consisting of 25 mM Tris-HCl (pH 8.0) and 100 mM potassium chloride are applied to the glass microchip surface in a chamber that can contain and seal the liquid. The solution is maintained at a specific temperature (determined by the capture oligo design) for at least three hours. Excess, non-hybridized RNA-protein fusions are removed by washing with 25 mM Tris-HCl (pH 8.0) and 50 mM potassium chloride for several minutes at the incubation temperature. The protein chip is subjected to two 15-minute washes, using a buffer that is more stringent and contains a lower salt concentration than the buffer used for the hybridization reaction.
- Generation of an Exemplary FLAG and HA11 Fusion Chip
- Using the techniques essentially as described above, exemplary FLAG and HA11 fusion chips were generated as follows.
- For silylation of the glass microchip surface, pre-cleaned 1×3 inch glass microscope slides (Goldseal, #3010) were treated with Nanostrip (Cyantek) for 15 minutes, 10% aqueous NaOH at 70° C. for 3 minutes, and 1% aqueous HCl for 1 minute, thoroughly rinsing with deionized water after each solution. The slides were then dried in a vacuum desiccator over anhydrous calcium sulfate for several hours. A 1% solution of aminopropytrimethoxysilane (Gelest, Inc.) in 95% acetone/5% water was prepared and allowed to hydrolyze for 20 minutes. The glass slides were immersed in the hydrolyzed silane solution for 5 minutes with gentle agitation. Excess silane was removed by subjecting the slides to ten 5-minute washes, using fresh portions of 95% acetone / 5% water for each wash, with gentle agitation. The slides were then cured by heating at 110° C. for 20 minutes.
- To derivatize with a homobifunctional linker, the silane treated slides were immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF/10% pyridine for two hours, with gentle agitation. The slides were washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides were stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- Capture oligos were then designed and synthesized by standard techniques. In particular, the RNA employed to make the FLAG epitope fusion (17 amino acids total) consisted of 5′-r(UAA UAC GAC UCA CUA UAG GGA CAA UUA CUA UUU ACA AUU ACA AUG GAC UAC AAG GAC GAU GAC GAU AAG GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG) (SEQ ID NO: 1). The RNA employed to make the HA11 epitope fusion (20 amino acids total) consisted of 5′-r(UAA UAC GAC UCA CUA UAG GGA CAA UUA CUA UUU ACA AUU ACA AUG UAC CCC UAC GAC GUG CCC GAC UAC GCC GGC GGC UGG UCC CAC CCC CAG UUC GAG AAG) (SEQ ID NO: 2). In addition, in each case, the following DNA linker, which also contained the essential puromycin moiety at its 3′-end, was ligated to the 3′-terminus of the RNA message:
5′-d(AAAAAAAAAAAAAAAAAAAAAAAAAAACC). (SEQ ID NO: 3) - Specific, non-interacting, and thermodynamically isoenergetic sequences along the target RNAs were identified to serve as capture points. The software program HybSimulator v2.2 (Advanced Gene Computing Technology, Inc.) facilitated the identifcation and analysis of potential capture probes. A single specific capture probe for each RNA was ultimately identified (CPflag and CPha11). In addition, two sequences common to each RNA (CPt7, CPtag) were also identified to serve as positive controls. Four non-sense sequences (CPau1, CPau5, CPirs, CPkt3) were generated as well to serve as negative controls. In total, eight unique sequences were selected. These oligonucleotides were prepared so that they could be attached to the chip surface at either the 3′- or 5′-terminus. Therefore, 16 capture probes were prepared comprising eight unique sequences. The following is a list of these capture probe sequences (5′ to 3′) (SEQ ID NOS: 4-11):
CPt7: TGTAAATAGTAATTGTCCC CPtag: CTTCTCGAACTGGG CPau1: CCTGTAGGTGTCCAT CPau5: CAGGTAGAAGTCGGT CPflag: CATCGTCCTTGTAGTC CPha11: CGTCGTAGGGGTA CPirs: CCGCTCCTGATGTA CPkt3: TCGGGAGGCATTG. - Oligonucleotide capture probes were chemically synthesized in the 3′ to 5′ direction by coupling standard phosphoramidite monomers using an automated DNA synthesizer (PE BioSystems Expedite 8909). Typically, 500 angstrom controlled-pore glass supports were used at the 0.2 micromole scale. In the case of 5′-attachment, after the desired probe sequence had been assembled (using A, G, C, and T monomers), four hexaethylene oxide phosphoramidite monomers (Glen Research) were added to the 5′-terminus. The coupling wait time was extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units were added in the same way. C-6 Amino phosphoramidite (Glen Research) was then added to the 5′ terminus; the coupling wait time was again extended to 15 minutes. The acetic anhydride capping step and the final acidic detritylation were eliminated. In the case of 3′-attachment, oligonucleotide synthesis began with a controlled-pore glass support bearing orthoganally protected primary hydroxyl and amino functionalities (Glen Research). Chain elongation began on the hydroxyl group, and the amino group remained protected during oligomer assembly, only being unveiled during the final deprotection. The first four monomers to be added were hexaethylene oxide units, followed by the standard A, G, C, and T monomers. All capture oligo sequences were cleaved from the solid support and deprotected with ammonium hydroxide, concentrated to dryness, precipitated in ethanol, and purified by reverse-phase HPLC using an acetonitrile gradient in triethylammonium acetate buffer. Apppropriate fractions from the HPLC were collected, evaporated to dryness in a vacuum centrifuge, and then coevaporated with a portion of water.
- To attach the purified, amine-labeled capture oligos, the oligos were adjusted to a concentration of 250 micromolar in 50 mM sodium carbonate buffer (pH 9.0) containing 10% glycerol. The oligos were then robotically applied (MicroGrid, BioRobotics) to the derivatized glass surface described above at defined positions in a 5×5×16 array pattern (384 spots) within a 20×20 mm area. The layout of these capture probes is shown schematically in FIG. 3. A 16-pin tool was used to transfer the liquid, producing 200 micron features with a pitch of 600 microns. Each sub-grid of 24 spots represented a single capture probe (i.e., 24 duplicate spots). The array was incubated at room temperature in a moisture-saturated environment for 12-18 hours. The attachment reaction was terminated by immersing the glass surface in an aqueous 1 % ammonia solution for five minutes with gentle agitation. The glass surface was then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. The array was then soaked in a 10×PBS (phosphate buffered saline) solution for 2 hours at room temperature, and then rinsed again for 5 minutes in distilled water.
- RNA-protein fusions between the peptides containing the FLAG and HA11 epitopes and their corresponding mRNAs were produced as generally described by Szostak et al., WO 98/31700; and Roberts and Szostak, Proc. Natl. Acad. Sci. USA 94:12297-12302, 1997. The polymerase chain reaction using Taq polymerase (Promega) was used to amplify the
sequences 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GAC TAC AAG GAC GAT GAC GAT AAG GGC GGC TGG TCC CAC CCC CAG TTC GAG AAG (SEQ ID NO: 12) and 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG TAC CCC TAC GAC GTG CCC GAC TAC GCC GGC GGC TGG TCC CAC CCC CAG TTC GAG AAG (SEQ ID NO: 13) for FLAG and HA11, respectively, using theoligonucleotide primers 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT (SEQ ID NO: 14) and 5′-AGCGGATGCCTTCTCGAACTGGGGGTGGGA (SEQ ID NO: 15). The resulting PCR products were transcribed in vitro using T7 RNA polymerase (Ambion), to produce an mRNA containing the coding region for the FLAG and HA11 epitopes and the TMV untranslated region. This RNA was ligated to aDNA linker 5′-AAA AAA AAA AAA AAA AAA AAA AAA AAA CC (SEQ ID NO: 3) containing a 5′ phosphate and a 3′ puromycin by T4 DNA ligase (Promega) in the presence of an 80:20 mixture of the following two DNA splints: - 5′-TGCAACGACCAACTTTTTTTTTTAGCGCATGC (SEQ ID NO: 16) and 5′-TGCAACGACCAACTTTTTTTTTNAGCGCATGC (SEQ ID NO: 17), each containing two biotin moieties at the 5′ terminus. The resulting RNA-DNA chimera was purified by binding to Immobilized NeutrAvidin (Pierce), washing to remove unligated material, and eluting by displacement using the
sequence 5′-GCATCCGCTAAAAAAAAAAGTTGGTCGTTGC (SEQ ID NO: 18). Subsequent translations were performed in rabbit reticulocyte lysate (Ambion) according to the manufacturer's instructions except that MgCl2 (150 mM) and KCl (425 mM) were added after 30 minutes to promote the formation of the puromycin-peptide bond. The RNA-peptide fusions were then purified by oligo dT affinity chromatography (Pharmacia), quantitated by scintillation counting of the incorporated vs. added 35S methionine (Amersham), and concentrated to a low volume via membrane filtration (MicroCon). - For hybridization of the fusions to the immobilized capture probes, aliquots of each of the FLAG and HA11 fusions, corresponding to 1.0 picomole each, were combined and adjusted to 5×SSC (saline sodium citrate)+0.02% Tween-20 in a volume of 20 microliters. The solution was applied to the glass chips described above, coverslips were placed on top, and the slides were placed in a moisture-saturated chamber at room temperature. After 18 hours the coverslips were removed, and the slides were washed sequentially with stirred 500 mL portions of 1×SSC+0.02% Tween-20, 1×SSC+0.02% Tween-20, and 1×SSC for 5 minutes each, followed by a brief rinse with 0.2×SSC. After removal of liquid the slides were allowed to briefly air-dry.
- To detect hybridization, the FLAG and HA11-fusion chip was exposed to a phosphorimage screen (Molecular Dynamics) for 60 hours by direct contact between the screen and the chip. This allowed identification of the areas that contained hybridized fusions, since the peptides contained a35S methionine radiolabel which was detectable by the phosphor storage screen. As shown in FIG. 4, analysis of the phosphorimage revealed that the fusions had successfully hybridized to their respective capture probes targeting specific areas of the RNA message (i.e.,.CPflag and CPha11). In addition, the four non-sense capture probes, which were not compelementary to any region of the FLAG or HA11 RNA, did not give any appreciable signal (i.e., CPau1, CPau5, CPirs, CPkt3). The positive control capture probe CPtag produced the expected signal, but the corresponding positive control capture probe CPt7 did not, likely due to degradation (e.g., exonuclease contamination) of the 5′-region of the targeted RNA. These results demonstrated the feasibility of addressing a mixture of peptides (as fusions) to specific locations on the surface of a chip. Both the 3′-attached capture probes and the 5′-attached capture probes were effective.
- A duplicate chip was probed with a monoclonal antibody that recognized the HA11 epitope. All of the following steps were performed at 4° C. Nonspecific sites were first blocked with a solution containing 1×PBS (phosphate buffered saline)+1% BSA (bovine serum albumin, RNAse free grade, Ambion)+0.02% Tween-20 for 1 hour under a coverslip. The blocking solution was removed and 50 microliters of HA.11 monoclonal antibody (100:1 dilution, Berkeley Antibody Co.) in 1×PBS+0.02% Tween-20 was applied to the chip under a coverslip. After 2 hours the coverslip was removed, and the chip was washed with three 50 mL portions of 1×PBS+0.02% Tween-20 for 5 minutes each, with gentle agitation. Excess liquid was removed and then 50 microliters of Cy3-labeled goat anti-mouse IgG (400:1 dilution, Amersham Pharmiacia Biotech) in 1×PBS+0.02% Tween-20 was added under a coverslip. After 1 hour the coverslip was removed, and the chip was washed in three 50 mL portions of 1×PBS+0.02% Tween-20 for 5 minutes each, with gentle agitation. Excess liquid was removed, and the chip was allowed to air-dry at room temperature. The chip was subsequently analyzed at 10 micron pixel resolution with a confocal laser scanner (ScanArray 3000, General Scanning) using preset excitation and emission wavelengths tuned to the Cy3 fluorophore. As shown in FIG. 5, the resulting fluorimage was in accord with the phosphorimage and demonstrated that the HA11 peptide, which was covalently linked to its RNA message and fixed to the chip surface, was functional and was available to interact with its binding partner (the HA11 monoclonal antibody). Moreover, although both the FLAG-fusion and the HA11 -fusion were presented on the chip surface, the HA11 monoclonal antibody was specific for its own epitope. In addition, the 3′-attachment capture probes generally provided a better signal than the 5′-attachment capture probes. Without being bound to a particular theory, this may reflect the greater accessibility of the epitope when it is oriented away from the chip surface.
- Generation of an Exemplary Myc Fusion Chip
- Using the techniques essentially as described above, an exemplary Myc fusion chip was also generated as follows.
- For silylation of the glass surface, select grade, low-iron content, pre-cleaned 25×75 mm glass microscope slides (VWR Scientific, #48311-950) were used as supplied. A 1% solution of aminopropytrimethoxysilane (Gelest, Inc.) in 95% acetone/5% water was prepared and allowed to hydrolyze for 20 minutes. The glass slides were immersed in the hydrolyzed silane solution for 5 minutes with gentle agitation. Excess silane was removed by subjecting the slides to ten 5-minute washes, using fresh portions of 95% acetone/5% water for each wash, with gentle agitation. The slides were then cured by heating at 110° C. for 20 minutes.
- To derivatize with a homobifunctional linker, the silane treated slides were immersed in a freshly prepared 0.2% solution of phenylene 1,4-diisothiocyanate (Aldrich Chemical Co.) in 90% DMF /10% pyridine for two hours, with gentle agitation. The slides were washed sequentially with 90% DMF/10% pyridine, methanol, and acetone. After air drying, the functionalized slides were stored at 0° C. in a vacuum desiccator over anhydrous calcium sulfate.
- The capture oligos were synthesized based on the Myc sequence. In particular, the RNA employed to make the c-myc fusion (33 amino acids total) consisted of the following sequence:
- 5′-r(UAAUACGACUCACUAUAGGGACAAUUACUAUUUACAAUUACAAUGGG GACAAUUACUAUUUACAAUUACAAUGGCUGAAGAACAGAAACUGAUCUCU GAAGAAGACCUGCUGCGUAAACGUCGUGAACAGCUGAAACACAAACUGGA ACAGCUGCGUAACUCUUGCGCU) (SEQ ID NO: 19). In addition, the following DNA linker, which also contains the essential puromycin moiety, was ligated to the 3′-terminus of the RNA message:
- 5′-d(AAAAAAAAAAAAAAAAAAAAAAAAAAACC) (SEQ ID NO: 3). Three non-overlapping and thermodynamically isoenergetic 20-mer sequences along the RNA were identified to serve as capture points. In addition, dA25 (on the ligated DNA) was selected as a fourth target area. The targeted sequences began at nucleotide positions 1, 33, 80, and 125 (CP01, CP33, CP80 and CP125, respectively). A mismatch sequence, derived from target sequence 33 and containing four internal and adjacent nucleotide mismatches, was also designed (CPmm). A non-sense sequence, corresponding to the reverse-orientation of CP33, was also utilized as a negative control (CPns). The following is a list of the capture probe sequences that were employed (5′ to 3′) (SEQ ID NOS: 20-25):
CP01: TTGTAAATAGTAATTGTCCC CP33: AGAGATCAGTTTCTGTTCTT CP80: AGTTTGTGTTTCAGCTGTTC CP125: TTTTTTTTTTTTTTTTTTTTTTTTT Cpmm: AGAGATCTCAATCTGTTCTT Cpns: TTCTTGTCTTTGACTAGAGA - Oligonucleotide capture probes were chemically synthesized in the 3′ to 5′ direction by coupling standard phosphoramidite monomers with an automated DNA synthesizer (PE BioSystems Expedite 8909). Typically, 500 angstrom controlled-pore glass supports were used at the 0.2 micromole scale. After the desired probe sequence had been assembled (using A, G, C, and T monomers), hexaethylene oxide phosphoramidite monomer (Glen Research) was added to the 5′-terminus. The coupling wait time was extended to 15 minutes by modifying the synthesizer program. Additional hexaethylene oxide monomer units were added in the same way. C-6 Amino phosphoramidite (Glen Research) was then added to the 5′ terminus; the coupling wait time was again extended to 15 minutes. The acetic anhydride capping step and the final acidic detritylation were eliminated. Capture oligo sequences were cleaved from the solid support and deprotected with ammonium hydroxide, concentrated to dryness, precipitated in ethanol, and purified by reverse-phase HPLC using an acetonitrile gradient in triethylammonium acetate buffer. Apppropriate fractions from the HPLC were collected, evaporated to dryness in a vacuum centrifuge, and then coevaporated with a portion of water.
- To attach these purified, amine-labeled capture oligos, the oligos were adjusted to a concentration of 500 micromolar in 100 mM sodium carbonate buffer (pH 9.0) and were applied to the derivatized glass surface at defined positions in a 6×6 array pattern (36 spots) within a 20×20 nm area (as shown in FIG. 6). CP01 was applied to locations A1, B1, C1 and A4, B4, C4. CP33 was applied to locations D1, E1, F1 and D4, E4, F4. CP80 was applied to locations A2, B2, C2 and A5, B5, C5. CP125 was applied to locations D2, E2, F2 and D5, E5, F5. Cpmm was applied to locations A3, B3, C3 and A6, B6, C6. Cpns was applied to locations D3, E3, F3 and D6, E6, F6. For manual deposition, aliquots of 0.2 microliter each were applied with a pipetman. The array was incubated at room temperature in a moisture-saturated environment for 12-18 hours. The attachment reaction was terminated by immersing the glass surface in an aqueous 1 % ammonia solution for five minutes with gentle agitation. The glass surface was then subjected to three 5-minute washes, using fresh portions of distilled water for each wash. The array was then soaked in a 10×PBS (phosphate buffered saline) solution for 2 hours at room temperature, and then rinsed again for 5 minutes in distilled water.
- RNA-protein fusions between a 33 amino acid peptide containing the c-myc epitope and its mRNA were produced as described by Szostak et al., WO 98/31700; and Roberts and Szostak, Proc. Natl. Acad. Sci. USA 94:12297-12302, 1997. The polymerase chain reaction using Taq polymerase (Promega) was used to amplify the
sequence 5′-AGC GCA AGA GTT ACG CAG CTG TTC CAG TTT GTG TTT CAG CTG TTC ACG ACG TTT ACG CAG CAG GTC TTC TTC AGA GAT CAG TTT CTG TTC TTC AGC CAT (SEQ ID NO: 26) usingoligonucleotide primers 5′-AGC GCA AGA GTT ACG CAG CTG (SEQ ID NO: 27) and 5′-TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GCT GAA GAA CAG AAA CT (SEQ ID NO: 28). The resulting PCR product was transcribed in vitro using T7 RNA polymerase (Ambion) to produce an mRNA containing the coding region for the c-myc epitope and the TMV untranslated region. This RNA was ligated to aDNA linker 5′-AAA AAA AAA AAA AAA AAA AAA AAA AAA CC (SEQ ID NO: 3) containing a 5′ phosphate and a 3′ puromycin by T4 DNA ligase (Promega) in the presence of a DNA splint with the sequence TTT TTT TTT TAG CGC AAG A (SEQ ID NO: 29). The resulting 154mer RNA-DNA chimera was purified by denaturing polyacrylamide gel electrophoresis (6% acrylamide). Translation was performed in rabbit reticulocyte lysate (Ambion) according to the manufacturer's instructions except that KCl (500 mM) was added after 30 minutes to promote the formation of the puromycin-peptide bond. The RNA-peptide fusion was purified by oligo dT affinity chromatography (Pharmacia), quantitated by scintillation counting of the incorporated vs. added 35S methionine (Amersham), and dried to a pellet. 2.5 pmol of the c-myc fusion was produced. - To hybridize to the capture probes, the dry myc-fusion pellet was taken up with 20 microliters of 5×SSC (saline sodium citrate)+0.02% SDS, mixed, and then briefly centrifuged. The solution was applied to the slide described above, a coverslip was placed on top, and the slide was placed in a moisture-saturated chamber at room temperature. After 18 hours the coverslip was removed, and the slide was washed sequentially with stirred 500 mL portions of 5×SSC+0.02% SDS, 2.5×SSC+0.01% SSC, 2.5×SSC, and 1.25×SSC for 5 minutes each. After removal of liquid the slide was allowed to briefly air-dry.
- To detect hybridization of the Myc fusions, the glass chip was exposed to a phosphorimage screen (Molecular Dynamics) for four hours by direct contact between the screen and the chip. This allowed identification of the areas that contained hybridized myc-fusion, since the myc peptide contained a35S methionine radiolabel which was detectable by the phosphor storage screen. As shown in FIG. 7, analysis of the phosphorimage revealed that the myc-fusion had successfully hybridized to each of the four capture probes that targeted the myc RNA message and DNA linker sequence. In addition, the non-sense capture probe, which was not complementary to any region of the myc RNA, did not give any appreciable signal. The capture probe sequence that contained several mismatches produced only a small amount of signal. These results demonstrated that it was possible to address a peptide (as a fusion) to a specific location on the surface of a chip.
- After phosphorimage analysis, the same chip was probed with a monoclonal antibody that recognized the c-myc epitope. All of the following steps were preformed at 4° C. Nonspecific sites were first blocked with a solution containing 1×PBS (phosphate buffered saline)+1% BSA (bovine serum albumin, Sigma Chemical Co.)+0.1 unit per microliter RNAse inhibitor (Ambion) for 1 hour under a coverslip. The blocking solution was removed, and 50 microliters of 9E10 monoclonal antibody in 1×PBS (400:1 dilution, Berkeley Antibody Co.) was applied to the chip under a coverslip. After 1 hour the coverslip was removed, and the chip was washed with three 50 mL portions of 1×PBS for 5 minutes each, with gentle agitation. Excess liquid was removed, and then 50 microliters of Cy3-labeled goat anti-mouse IgG in 1×PBS (400:1 dilution, Amersham Pharmacia Biotech) was added under a coverslip. After 1 hour the coverslip was removed, and the chip was washed in three 50 mL portions of 1×PBS for 5 minutes each, with gentle agitation. Excess liquid was removed, and the chip was allowed to air-dry at room temperature. The chip was subsequently analyzed at 10 micron pixel resolution with a confocal laser scanner (ScanArray 3000, General Scanning) using preset excitation and emission wavelengths tuned to the Cy3 fluorophore. As shown in FIG. 8, the resulting fluorimage was in accord with the phosphorimage and demonstrated that the myc peptide, which was covalently linked to its RNA message and fixed to the chip surface, was functional and was available to interact with its binding partner (the monoclonal antibody).
- All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
- Other Embodiments
- From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
-
1 29 1 99 RNA Artificial Sequence Oligonucleotide employed to construct FLAG epitope fusion 1 uaauacgacu cacuauaggg acaauuacua uuuacaauua caauggacua caaggacgau 60 gacgauaagg gcggcugguc ccacccccag uucgagaag 99 2 102 RNA Artificial Sequence Oligonucleotide employed to construct HA11 epitope fusion 2 uaauacgacu cacuauaggg acaauuacua uuuacaauua caauguaccc cuacgacgug 60 cccgacuacg ccggcggcug gucccacccc caguucgaga ag 102 3 29 DNA Artificial Sequence Oligonucleotide used for attaching puromycin 3 aaaaaaaaaa aaaaaaaaaa aaaaaaacc 29 4 19 DNA Artificial Sequence Oligonucleotide used for chip attachment 4 tgtaaatagt aattgtccc 19 5 14 DNA Artificial Sequence Oligonucleotide used for chip attachment 5 cttctcgaac tggg 14 6 15 DNA Artificial Sequence Oligonucleotide used for chip attachment 6 cctgtaggtg tccat 15 7 15 DNA Artificial Sequence Oligonucleotide used for chip attachment 7 caggtagaag tcggt 15 8 16 DNA Artificial Sequence Oligonucleotide used for chip attachment 8 catcgtcctt gtagtc 16 9 13 DNA Artificial Sequence Oligonucleotide used for chip attachment 9 cgtcgtaggg gta 13 10 14 DNA Artificial Sequence Oligonucleotide used for chip attachment 10 ccgctcctga tgta 14 11 13 DNA Artificial Sequence Oligonucleotide used for chip attachment 11 tcgggaggca ttg 13 12 99 DNA Artificial Sequence FLAG amplification sequence 12 taatacgact cactataggg acaattacta tttacaatta caatggacta caaggacgat 60 gacgataagg gcggctggtc ccacccccag ttcgagaag 99 13 102 DNA Artificial Sequence HA11 amplification sequence 13 taatacgact cactataggg acaattacta tttacaatta caatgtaccc ctacgacgtg 60 cccgactacg ccggcggctg gtcccacccc cagttcgaga ag 102 14 39 DNA Artificial Sequence Oligonucleotide used for PCR 14 taatacgact cactataggg acaattacta tttacaatt 39 15 30 DNA Artificial Sequence Oligonucleotide used for PCR 15 agcggatgcc ttctcgaact gggggtggga 30 16 32 DNA Artificial Sequence Oligonucleotide used as a splint containing biotin moiety at 5′ terminus 16 tgcaacgacc aacttttttt tttagcgcat gc 32 17 32 DNA Artificial Sequence Oligonucleotide used as a splint containing biotin moiety at 5′ terminus 17 tgcaacgacc aacttttttt ttnagcgcat gc 32 18 31 DNA Artificial Sequence Oligonucleotide used for elution displacement 18 gcatccgcta aaaaaaaaag ttggtcgttg c 31 19 169 RNA Artificial Sequence Oligonucleotide used to make c-myc fusion 19 uaauacgacu cacuauaggg acaauuacua uuuacaauua caauggggac aauuacuauu 60 uacaauuaca auggcugaag aacagaaacu gaucucugaa gaagaccugc ugcguaaacg 120 ucgugaacag cugaaacaca aacuggaaca gcugcguaac ucuugcgcu 169 20 20 DNA Artificial Sequence Capture probe sequence 20 ttgtaaatag taattgtccc 20 21 20 DNA Artificial Sequence Capture probe sequence 21 agagatcagt ttctgttctt 20 22 20 DNA Artificial Sequence Capture probe sequence 22 agtttgtgtt tcagctgttc 20 23 25 DNA Artificial Sequence Capture probe sequence 23 tttttttttt tttttttttt ttttt 25 24 20 DNA Artificial Sequence Capture probe sequence 24 agagatctca atctgttctt 20 25 20 DNA Artificial Sequence Capture probe sequence 25 ttcttgtctt tgactagaga 20 26 99 DNA Artificial Sequence c-myc epitope amplification sequence 26 agcgcaagag ttacgcagct gttccagttt gtgtttcagc tgttcacgac gtttacgcag 60 caggtcttct tcagagatca gtttctgttc ttcagccat 99 27 21 DNA Artificial Sequence Oligonucleotide used for PCR 27 agcgcaagag ttacgcagct g 21 28 62 DNA Artificial Sequence Oligonucleotide used for PCR 28 taatacgact cactataggg acaattacta tttacaatta caatggctga agaacagaaa 60 ct 62 29 19 DNA Artificial Sequence Oligonucleotide used as a splint 29 tttttttttt agcgcaaga 19
Claims (29)
1. A solid support having a linker layer on its surface, said linker layer being linked to an array of immobilized capture probes, each of said capture probes comprising a non-nucleosidic spacer group located proximal to the linker layer and an oligonucleotide sequence located distal to the linker layer, wherein said oligonucleotide sequence is bound to a nucleic acid-protein fusion.
2. The solid support of claim 1 , wherein said nucleic acid-protein fusion is an RNA-protein fusion.
3. The solid support of claim 1 , wherein said oligonucleotide sequence is bound to said nucleic acid-protein fusion by base pairing.
4. The solid support of claim 1 , wherein the protein is encoded by the nucleic acid.
5. The solid support of claim 1 , wherein said spacer group comprises polyalkylene oxide.
6. The solid support of claim 1 , wherein said spacer group comprises polyethylene oxide.
7. The solid support of claim 1 , wherein said spacer group comprises hexaethylene oxide.
8. The solid support of claim 1 , wherein said capture probe comprises a photocleavable linker.
9. The solid support of claim 1 , wherein said oligonucleotide sequence comprises a modified base.
10. The solid support of claim 9 , wherein said modified base is 5-propyne pyrimidine.
11. The solid support of claim 1 , wherein said oligonucleotide sequence comprises an internucleotide analog.
12. The solid support of claim 11 , wherein said internucleotide analog is a 3′-phosphoramidate linkage.
13. The solid support of claim 1 , wherein said oligonucleotide sequence comprises a carbohydrate modification.
14. The solid support of claim 13 , wherein said carbohydrate modification is a 2′-O-methyl group.
15. The solid support of claim 1 , wherein said nucleic acid-protein fusion comprises a hybridization tag sequence.
16. The solid support of claim 15 , wherein said hybridization tag sequence comprises a modified base.
17. The solid support of claim 15 , wherein said hybridization tag sequence comprises an intemucleotide analog.
18. The solid support of claim 1 , wherein each of said capture probes further comprises a reactive moiety.
19. The solid support of claim 18 , wherein said reactive moiety is a primary amino group.
20. The solid support of claim 1 , wherein said solid support is a glass or silica-based chip.
21. The solid support of claim 1 , wherein said nucleic acid-protein fusion is covalently linked to said capture probe.
22. The solid support of claim 21 , wherein said capture probe comprises one or more psoralen moieties.
23. A solid support having a linker layer on its surface, said linker layer being linked to an array of immobilized capture probes, wherein each of said capture probes is attached to the linker layer of said solid support through a non-nucleosidic spacer group, and wherein each of said capture probes comprises an oligonucleotide sequence to which a nucleic acid-protein fusion is bound.
24. The solid support of claim 23 , wherein said nucleic acid-protein fusion is an RNA-protein fusion.
25. A solid support comprising an array of immobilized capture probes, each of said capture probes comprising a non-nucleosidic spacer group and an oligonucleotide sequence to which a ribosome display particle is bound.
26. A method for preparing a solid support, said method comprising the steps of:
(a) preparing a capture probe by linking a spacer group to an oligonucleotide sequence;
(b) attaching said capture probe to said solid support; and
(c) binding a nucleic acid-protein fusion to said capture probe.
27. The method of claim 26 , wherein said nucleic acid-protein fusion is an RNA-protein fusion.
28. A method for preparing a solid support, said method comprising the steps of:
(a) attaching a spacer group to a surface of said solid support;
(b) attaching a bifunctional linker to said spacer group;
(c) attaching a capture probe to said bifunctional linker; and
(d) binding a nucleic acid-protein fusion to said capture probe.
29. The method of claim 28 , wherein said nucleic acid-protein fusion is an RNA-protein fusion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/348,627 US20030143616A1 (en) | 1998-04-03 | 2003-01-22 | Addressable protein arrays |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8068698P | 1998-04-03 | 1998-04-03 | |
US09/282,734 US6537749B2 (en) | 1998-04-03 | 1999-03-31 | Addressable protein arrays |
US10/348,627 US20030143616A1 (en) | 1998-04-03 | 2003-01-22 | Addressable protein arrays |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/282,734 Division US6537749B2 (en) | 1998-04-03 | 1999-03-31 | Addressable protein arrays |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030143616A1 true US20030143616A1 (en) | 2003-07-31 |
Family
ID=22158971
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/282,734 Expired - Lifetime US6537749B2 (en) | 1998-04-03 | 1999-03-31 | Addressable protein arrays |
US10/348,627 Abandoned US20030143616A1 (en) | 1998-04-03 | 2003-01-22 | Addressable protein arrays |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/282,734 Expired - Lifetime US6537749B2 (en) | 1998-04-03 | 1999-03-31 | Addressable protein arrays |
Country Status (9)
Country | Link |
---|---|
US (2) | US6537749B2 (en) |
EP (1) | EP1068356B8 (en) |
JP (1) | JP2002510505A (en) |
AT (1) | ATE340870T1 (en) |
AU (1) | AU3463699A (en) |
CA (1) | CA2323638A1 (en) |
DE (1) | DE69933369D1 (en) |
IL (1) | IL138668A0 (en) |
WO (1) | WO1999051773A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040086883A1 (en) * | 2000-08-11 | 2004-05-06 | Hermann Gaub | Method and device for characterising and/or for detecting a bonding complex |
US20050084855A1 (en) * | 2001-06-01 | 2005-04-21 | Kerstin Blank | Method for determining an analyte |
WO2005045075A2 (en) * | 2003-08-12 | 2005-05-19 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
EP1538221A1 (en) * | 2003-12-02 | 2005-06-08 | Roche Diagnostics GmbH | Oligonucleotides containing molecular rods |
WO2007097740A2 (en) * | 2005-02-11 | 2007-08-30 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
EP1994209A2 (en) * | 2006-01-03 | 2008-11-26 | The President and Fellows of Harvard College | Small molecule printing |
US20090099027A1 (en) * | 2007-08-23 | 2009-04-16 | Applied Biosystems Inc. | Methods of Modifying Support Surfaces for the Immobilization of Particles and the Use of the Immobilized Particles for Analyzing Nucleic Acids |
US20100086927A1 (en) * | 2008-07-23 | 2010-04-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
US20110151510A1 (en) * | 2006-03-28 | 2011-06-23 | Fujitsu Limited | Functional molecule and manufacturing method therefor |
WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
Families Citing this family (314)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458530B1 (en) * | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
CA2255599C (en) | 1996-04-25 | 2006-09-05 | Bioarray Solutions, Llc | Light-controlled electrokinetic assembly of particles near surfaces |
US6990221B2 (en) * | 1998-02-07 | 2006-01-24 | Biodiscovery, Inc. | Automated DNA array image segmentation and analysis |
US6349144B1 (en) * | 1998-02-07 | 2002-02-19 | Biodiscovery, Inc. | Automated DNA array segmentation and analysis |
US6312927B1 (en) | 1998-08-17 | 2001-11-06 | Phylos, Inc. | Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) * | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6849397B2 (en) * | 1999-05-04 | 2005-02-01 | Wisconsin Alumni Research Foundation | Label-free detection of nucleic acids via surface plasmon resonance |
DE19923966C2 (en) * | 1999-05-25 | 2003-04-24 | Phylos Inc | Detection system for the separation of sample components, its production and use |
CA2372795A1 (en) | 1999-07-12 | 2001-01-18 | Robert G. Kuimelis | C-terminal protein tagging |
ATE542916T1 (en) | 1999-08-18 | 2012-02-15 | Illumina Inc | METHODS FOR GENERATING OLIGONUCLEOTIDE SOLUTIONS |
WO2001016352A1 (en) * | 1999-08-27 | 2001-03-08 | Phylos, Inc. | Methods for encoding and sorting in vitro translated proteins |
US6839454B1 (en) * | 1999-09-30 | 2005-01-04 | Biodiscovery, Inc. | System and method for automatically identifying sub-grids in a microarray |
US6731781B1 (en) * | 1999-09-30 | 2004-05-04 | Biodiscovery, Inc. | System and method for automatically processing microarrays |
US7099502B2 (en) * | 1999-10-12 | 2006-08-29 | Biodiscovery, Inc. | System and method for automatically processing microarrays |
DE19959857C1 (en) * | 1999-12-10 | 2001-06-28 | Aventis Res & Tech Gmbh & Co | Test system for the detection of analytes and a method for the production and use |
FR2802550B1 (en) * | 1999-12-17 | 2004-03-05 | Centre Nat Rech Scient | BIOCUCES, PREPARATION AND USES |
AU3163101A (en) * | 1999-12-21 | 2001-07-03 | Vbc-Genomics Bioscience Research Gmbh | Compound comprising a nucleic acid moiety and an organo-silane moiety |
WO2001053539A1 (en) * | 2000-01-24 | 2001-07-26 | Phylos, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
US7816098B2 (en) | 2000-01-31 | 2010-10-19 | Sense Proteomic Limited | Methods of making and using a protein array |
DE60142765D1 (en) * | 2000-01-31 | 2010-09-23 | Sense Proteomic Ltd | METHOD FOR PRODUCING PROTEIN EXPRESSION ARRAYS AND APPLYING THE SAME IN FAST SCREENING |
WO2001064882A2 (en) | 2000-02-29 | 2001-09-07 | Millennium Pharmaceuticals, Inc. | 1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor |
GB2360282A (en) * | 2000-03-17 | 2001-09-19 | Bioinvent Int Ab | Making and using micro-arrays of biological materials |
EP1136567A1 (en) * | 2000-03-24 | 2001-09-26 | Advanced Array Technologies S.A. | Method and kit for the screening, the detection and /or the quantification of transcriptional factors |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US20020028455A1 (en) * | 2000-05-03 | 2002-03-07 | Laibinis Paul E. | Methods and reagents for assembling molecules on solid supports |
US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
US7410761B2 (en) | 2000-05-19 | 2008-08-12 | Proteonova, Inc. | System for rapid identification and selection of nucleic acids and polypeptides, and method thereof |
US20040229271A1 (en) | 2000-05-19 | 2004-11-18 | Williams Richard B. | Compositions and methods for the identification and selection of nucleic acids and polypeptides |
WO2001090414A1 (en) * | 2000-05-19 | 2001-11-29 | Williams Richard B | In vitro evolution of nucleic acids and encoded polypeptide |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
US7270954B1 (en) * | 2000-06-30 | 2007-09-18 | Iris Biotechnologies, Inc. | Hybridization of target DNA with immobilized nucleic acid analogs |
GB0016836D0 (en) * | 2000-07-07 | 2000-08-30 | Lee Helen | Improved dipstick assays (1) |
DE10033194C2 (en) * | 2000-07-07 | 2002-07-18 | Aventis Res & Tech Gmbh & Co | Bio probes and their use |
US7094568B2 (en) | 2000-08-17 | 2006-08-22 | Sense Proteomic Ltd. | Method for producing proteins tagged at the N- or C-terminus |
CN1494589A (en) * | 2000-08-17 | 2004-05-05 | �������ɭ | Method |
US6539102B1 (en) | 2000-09-01 | 2003-03-25 | Large Scale Proteomics | Reference database |
US6980674B2 (en) | 2000-09-01 | 2005-12-27 | Large Scale Proteomics Corp. | Reference database |
AU2001292959A1 (en) * | 2000-09-22 | 2002-04-02 | Clontech Laboratories, Inc. | Highly sensitive proteomic analysis methods and kits and systems for practicing the same |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US6897067B2 (en) | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6902933B2 (en) | 2000-11-03 | 2005-06-07 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
JP2005505231A (en) * | 2000-11-03 | 2005-02-24 | リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Surface transfection and expression methods |
US7351575B2 (en) | 2000-11-08 | 2008-04-01 | Surface Logix, Inc. | Methods for processing biological materials using peelable and resealable devices |
US6803205B2 (en) | 2000-11-08 | 2004-10-12 | Surface Logix, Inc. | Methods of measuring enzyme activity using peelable and resealable devices |
US7001740B2 (en) | 2000-11-08 | 2006-02-21 | Surface Logix, Inc. | Methods of arraying biological materials using peelable and resealable devices |
US6967074B2 (en) | 2000-11-08 | 2005-11-22 | Surface Logix, Inc. | Methods of detecting immobilized biomolecules |
US7371563B2 (en) | 2000-11-08 | 2008-05-13 | Surface Logix, Inc. | Peelable and resealable devices for biochemical assays |
US7439056B2 (en) | 2000-11-08 | 2008-10-21 | Surface Logix Inc. | Peelable and resealable devices for arraying materials |
EP1348034B1 (en) * | 2000-11-15 | 2016-07-20 | Minerva Biotechnologies Corporation | Oligonucleotide identifiers |
US6905816B2 (en) | 2000-11-27 | 2005-06-14 | Intelligent Medical Devices, Inc. | Clinically intelligent diagnostic devices and methods |
WO2002059601A1 (en) | 2001-01-23 | 2002-08-01 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
US7981842B2 (en) * | 2001-06-08 | 2011-07-19 | Panomics, Inc. | Method for detecting transcription factor-protein interactions |
US6924113B2 (en) * | 2001-06-08 | 2005-08-02 | Panomics, Inc. | Method and kit for isolating DNA probes that bind to activated transcription factors |
WO2002102820A1 (en) | 2001-06-20 | 2002-12-27 | Nuevolution A/S | Nucleoside derivatives for library preparation |
US6951725B2 (en) * | 2001-06-21 | 2005-10-04 | Compound Therapeutics, Inc. | In vitro protein interaction detection systems |
US7262063B2 (en) | 2001-06-21 | 2007-08-28 | Bio Array Solutions, Ltd. | Directed assembly of functional heterostructures |
US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
US9777312B2 (en) | 2001-06-30 | 2017-10-03 | Enzo Life Sciences, Inc. | Dual polarity analysis of nucleic acids |
US7172905B2 (en) | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
DE10145226A1 (en) * | 2001-09-13 | 2003-04-10 | Lifebits Ag | Manufacture of carrier-bound molecules |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
KR20040068122A (en) | 2001-10-15 | 2004-07-30 | 바이오어레이 솔루션스 리미티드 | Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
AU2002365404A1 (en) * | 2001-11-27 | 2003-06-10 | Compound Therapeutics, Inc. | Solid-phase immobilization of proteins and peptides |
WO2003064604A2 (en) * | 2002-01-25 | 2003-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Translation profiling |
US7413854B2 (en) | 2002-03-15 | 2008-08-19 | Nuevolution A/S | Method for synthesising templated molecules |
US20030228709A1 (en) * | 2002-03-25 | 2003-12-11 | Kozlowski Roland Zbignieiw | Arrays |
US6916621B2 (en) | 2002-03-27 | 2005-07-12 | Spectral Genomics, Inc. | Methods for array-based comparitive binding assays |
US20030194709A1 (en) * | 2002-04-10 | 2003-10-16 | Xing Yang | Hydrophobic zone device |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
EP1497418B1 (en) | 2002-04-19 | 2012-10-17 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
JP2004028953A (en) * | 2002-06-28 | 2004-01-29 | Dna Chip Research Inc | Substrate and method for fixing biorelated substance or chemical substance, and method for coating substrate |
EP1521961A2 (en) * | 2002-07-05 | 2005-04-13 | The University of Chicago | Characterization of biochips containing self-assembled monolayers with maldi-tof-ms |
US10730906B2 (en) | 2002-08-01 | 2020-08-04 | Nuevolutions A/S | Multi-step synthesis of templated molecules |
US7041453B2 (en) * | 2002-08-22 | 2006-05-09 | Bioarray Solutions Ltd. | Molecular constructs and methods of use for detection of biochemical reactions |
US7512496B2 (en) * | 2002-09-25 | 2009-03-31 | Soheil Shams | Apparatus, method, and computer program product for determining confidence measures and combined confidence measures for assessing the quality of microarrays |
EP3299463B1 (en) | 2002-10-30 | 2020-10-21 | Nuevolution A/S | Enzymatic encoding |
US20030153013A1 (en) * | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
US7526114B2 (en) | 2002-11-15 | 2009-04-28 | Bioarray Solutions Ltd. | Analysis, secure access to, and transmission of array images |
JP2004184312A (en) * | 2002-12-05 | 2004-07-02 | Yokogawa Electric Corp | Biopolymer detection method and biochip |
EP1573044A4 (en) | 2002-12-18 | 2006-07-05 | Ciphergen Biosystems Inc | Serum biomarkers in lung cancer |
WO2004056994A2 (en) | 2002-12-19 | 2004-07-08 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
ES2362424T3 (en) | 2003-01-07 | 2011-07-05 | Dyax Corporation | KUNITZ DOMAIN LIBRARY. |
JP4741458B2 (en) | 2003-01-16 | 2011-08-03 | カプロテック・バイオアナリティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Method for analyzing capture compounds, collections thereof, and proteomes and composite compositions |
EP1597394A2 (en) * | 2003-02-21 | 2005-11-23 | Nuevolution A/S | A method for obtaining structural information about an encoded molecule |
WO2004074429A2 (en) | 2003-02-21 | 2004-09-02 | Nuevolution A/S | Method for producing second-generation library |
EP3023498B1 (en) | 2003-03-06 | 2018-11-28 | BASF Enzymes LLC | Amylases, nucleic acids encoding them and methods for making and using them |
MX295545B (en) | 2003-03-07 | 2012-02-03 | Diversa Corp | Hydrolases, nucleic acids encoding them and mehods for making and using them. |
DE602004019764D1 (en) | 2003-03-20 | 2009-04-16 | Nuevolution As | LIGATION-RELATED CODING OF SMALL MOLECULES |
US7592434B2 (en) | 2003-04-04 | 2009-09-22 | Verenium Corporation | Pectate lyases, nucleic encoding them and methods for making and using them |
WO2004094460A2 (en) | 2003-04-17 | 2004-11-04 | Ciphergen Biosystems, Inc. | Polypeptides related to natriuretic peptides and methods of their identification and use |
EP2404931A1 (en) | 2003-07-02 | 2012-01-11 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
CA2534661A1 (en) | 2003-08-08 | 2005-02-17 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
CA2535526C (en) | 2003-08-11 | 2015-09-29 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
WO2005026387A1 (en) | 2003-09-18 | 2005-03-24 | Nuevolution A/S | A method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
CA2539824C (en) | 2003-09-22 | 2015-02-03 | Xinwen Wang | Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules |
AU2004286252A1 (en) | 2003-10-28 | 2005-05-12 | Bioarray Solutions Ltd. | Optimization of gene expression analysis using immobilized capture probes |
JP4796967B2 (en) | 2003-11-07 | 2011-10-19 | ヴァーミリオン インコーポレイテッド | Biomarkers for Alzheimer's disease |
KR20060129246A (en) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | Inhibitors of type 2 vascular endothelial growth factor receptors |
WO2005055812A2 (en) | 2003-12-05 | 2005-06-23 | Ciphergen Biosystems, Inc. | Serum biomarkers for chagas disease |
AU2005220746A1 (en) | 2004-03-05 | 2005-09-22 | Medical College Of Ohio | Methods and compositions for assessing nucleic acids and alleles |
EP1730277B1 (en) | 2004-03-22 | 2009-10-28 | Nuevolution A/S | Ligational encoding using building block oligonucleotides |
AU2005227785A1 (en) * | 2004-03-31 | 2005-10-13 | Takayuki Doi | Labeling substance and chimera substance, process for preparing these substances, and method of biosubstance trapping, structural analysis or/and identification with use of the labeling substance |
EP1745157A4 (en) | 2004-04-12 | 2008-06-11 | Ohio Med College | Methods and compositions for assaying analytes |
WO2005108615A2 (en) * | 2004-04-14 | 2005-11-17 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
EP2207033B1 (en) | 2004-04-15 | 2014-06-18 | University of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
WO2005103281A2 (en) | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
US7585859B2 (en) | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
CA2567627C (en) | 2004-05-20 | 2014-09-30 | Quest Diagnostics Investments Incorporated | Single label comparative hybridization |
AU2005264938B2 (en) | 2004-06-16 | 2011-11-24 | Verenium Corporation | Compositions and methods for enzymatic decolorization of chlorophyll |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
WO2006074360A2 (en) | 2005-01-06 | 2006-07-13 | Eastern Virginia Medical School | Apolipoprotein a-ii isoform as a biomarker for prostate cancer |
DE602006018861D1 (en) | 2005-01-27 | 2011-01-27 | Quest Diagnostics Invest Inc | FAST COMPARATIVE GENOM HYBRIDIZATION |
EP2520669A3 (en) | 2005-02-07 | 2013-02-27 | GeneNews Inc. | Mild osteoathritis biomarkers and uses thereof |
WO2006099207A2 (en) | 2005-03-10 | 2006-09-21 | Diversa Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
NZ594810A (en) | 2005-03-15 | 2012-12-21 | Verenium Corp | Cellulases, nucleic acids encoding them and methods for making and using them |
US8048638B2 (en) | 2005-04-01 | 2011-11-01 | University Of Florida Research Foundation, Inc. | Biomarkers of liver injury |
AU2006232370B2 (en) | 2005-04-01 | 2011-10-06 | Banyan Biomarkers | Biomakers of liver injury |
KR20080027775A (en) | 2005-05-17 | 2008-03-28 | 플렉시콘, 인코퍼레이티드 | Pyrrole(2,3-b)pyridine derivatives protein kinase inhibitors |
WO2007002527A2 (en) | 2005-06-24 | 2007-01-04 | Ciphergen Biosystems, Inc. | BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN |
ATE518007T1 (en) | 2005-10-21 | 2011-08-15 | Genenews Inc | METHOD AND APPARATUS FOR CORRELING LEVELS OF BIOMARKER PRODUCTS WITH DISEASES |
EP1951906B1 (en) | 2005-11-10 | 2010-12-22 | Bristol-Myers Squibb Pharma Company | Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers |
US8076074B2 (en) | 2005-11-29 | 2011-12-13 | Quest Diagnostics Investments Incorporated | Balanced translocation in comparative hybridization |
LT3305900T (en) | 2005-12-01 | 2021-11-10 | Nuevolution A/S | Enzymatic encoding methods for efficient synthesis of large libraries |
WO2007070809A2 (en) * | 2005-12-12 | 2007-06-21 | Mcgill University | Biomarkers for babesia |
WO2007092314A2 (en) | 2006-02-02 | 2007-08-16 | Verenium Corporation | Esterases and related nucleic acids and methods |
DK2450439T3 (en) | 2006-02-10 | 2014-02-10 | Verenium Corp | Cellulose-degrading enzymes, nucleic acids encoding them, and methods of preparing and utilizing them |
EP2548955A1 (en) | 2006-02-14 | 2013-01-23 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
KR101588539B1 (en) | 2006-03-07 | 2016-01-25 | 바스프 엔자임스 엘엘씨 | Aldolases, nucleic acids encoding them and methods for making and using them |
EP2112227B1 (en) | 2006-03-07 | 2013-05-15 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
WO2007106466A2 (en) | 2006-03-11 | 2007-09-20 | The Board Of Trustees Of The Leland Stanford Junior University | Beta-2 microglobulin as a biomarker for peripheral artery disease |
US8178316B2 (en) | 2006-06-29 | 2012-05-15 | President And Fellows Of Harvard College | Evaluating proteins |
TWI369402B (en) | 2006-07-05 | 2012-08-01 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
US20100003189A1 (en) | 2006-07-14 | 2010-01-07 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
CA2659745A1 (en) * | 2006-08-02 | 2008-02-07 | California Institute Of Technology | Methods and systems for detecting and/or sorting targets |
BRPI0714876B1 (en) | 2006-08-04 | 2022-04-19 | Verenium Corporation | Isolated, synthetic or recombinant nucleic acid, expression cassette, cloning vector or vehicle, transformed bacterial, fungal or yeast cell, isolated, synthetic or recombinant polypeptide, composition, as well as production methods and uses thereof |
WO2008036863A2 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
CN113789316A (en) | 2006-09-21 | 2021-12-14 | 巴斯夫酶有限责任公司 | Phytases, nucleic acids encoding them and methods of making and using them |
US20110143953A1 (en) * | 2006-10-16 | 2011-06-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Synthetic Antibodies |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US8288110B2 (en) * | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
CA2673525C (en) | 2006-12-21 | 2017-12-05 | Verenium Corporation | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
CA2674721C (en) | 2007-01-30 | 2018-04-03 | Verenium Corporation | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
GB2447786C (en) | 2007-03-22 | 2011-11-09 | Heptares Therapeutics Ltd | Mutant G-protein coupled receptor proteins and methods for selecting them |
EP2210099A4 (en) | 2007-03-27 | 2011-03-16 | Vermillion Inc | Biomarkers for ovarian cancer |
MX2009010997A (en) | 2007-04-13 | 2009-11-02 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof. |
EP3196310B1 (en) | 2007-04-27 | 2020-07-08 | The Regents of The University of California | Plant co2 sensors, nucleic acids encoding them, and methods for making and using them |
EP2162552A4 (en) | 2007-05-11 | 2010-06-30 | Univ Johns Hopkins | Biomarkers for melanoma |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US7507539B2 (en) | 2007-07-30 | 2009-03-24 | Quest Diagnostics Investments Incorporated | Substractive single label comparative hybridization |
WO2009045627A2 (en) | 2007-10-03 | 2009-04-09 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
US7811810B2 (en) | 2007-10-25 | 2010-10-12 | Industrial Technology Research Institute | Bioassay system including optical detection apparatuses, and method for detecting biomolecules |
US7767441B2 (en) * | 2007-10-25 | 2010-08-03 | Industrial Technology Research Institute | Bioassay system including optical detection apparatuses, and method for detecting biomolecules |
EP3536336A1 (en) | 2007-11-30 | 2019-09-11 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
ES2334084B1 (en) | 2007-12-21 | 2011-01-24 | Inst Cientifico Tecnol Navarra | GENETIC MARKERS FOR THE FORECAST OF MULTIPLE SCLEROSIS. |
JP5563990B2 (en) | 2008-01-03 | 2014-07-30 | ヴェレニウム コーポレイション | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
GB0802474D0 (en) * | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
MX2010008874A (en) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Targeted therapeutics based on engineered proteins that bind egfr. |
DE08718604T1 (en) * | 2008-03-05 | 2009-12-24 | Medical Research Council | crystal structure |
EP3156925A3 (en) | 2008-03-10 | 2017-06-21 | Lineagen, Inc. | Copd biomarker signatures |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
CN101550441B (en) * | 2008-04-01 | 2011-11-23 | 博尔诚(北京)科技有限公司 | Method for high-flux analysis of specimen containing biological marker and sample bank preparation |
EP2281078B1 (en) | 2008-04-24 | 2014-10-22 | Dyax Corporation | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
CA2722082C (en) | 2008-04-25 | 2021-11-09 | Christopher Tenhoor | Fc receptor binding proteins |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AR071874A1 (en) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE |
CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
WO2010123720A1 (en) | 2009-04-23 | 2010-10-28 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
EP2316030B1 (en) | 2008-07-25 | 2019-08-21 | Wagner, Richard W. | Protein screeing methods |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
JP5586607B2 (en) | 2008-08-29 | 2014-09-10 | ヤンセン バイオテツク,インコーポレーテツド | Markers and methods for evaluating and treating ulcerative colitis and related diseases using a 20 gene panel |
US20100093563A1 (en) | 2008-09-22 | 2010-04-15 | Robert Anthony Williamson | Methods and vectors for display of molecules and displayed molecules and collections |
CA2679750A1 (en) * | 2008-09-23 | 2010-03-23 | Nexus Dx, Inc. | Methods for detecting nucleic acids in a sample |
EP2169078A1 (en) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Methods and kits for the diagnosis and the staging of colorectal cancer |
TW201028432A (en) * | 2008-09-30 | 2010-08-01 | Abbott Lab | Improved antibody libraries |
CA2740440A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis |
EP2352998A4 (en) | 2008-11-07 | 2011-09-21 | Centocor Ortho Biotech Inc | Markers and methods for assessing and treating lupus patients susceptible to photoprovocation |
TWI496582B (en) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
JP5684724B2 (en) | 2008-12-30 | 2015-03-18 | ヤンセン バイオテツク,インコーポレーテツド | Serum markers to predict clinical response to anti-TNFα antibodies in patients with ankylosing spondylitis |
WO2010087985A2 (en) | 2009-01-28 | 2010-08-05 | Yale University | Novel markers for detection of complications resulting from in utero encounters |
EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
EP2406399B1 (en) | 2009-03-09 | 2018-02-14 | Bioatla, LLC | Mirac proteins |
CR20170089A (en) | 2009-04-03 | 2017-07-17 | Plexxikon Inc | PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME |
CN102459303B (en) | 2009-05-21 | 2016-06-29 | 巴斯夫酶有限责任公司 | Phytase, the nucleic acid encoding them and preparation and their method of use |
AU2010256880B2 (en) | 2009-06-02 | 2015-01-22 | Opko Health, Inc. | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases |
GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
JP2013504602A (en) | 2009-09-14 | 2013-02-07 | ダイアックス コーポレーション | Newly designed gene package library containing HCCR3 |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
AU2010298000A1 (en) | 2009-09-25 | 2012-04-05 | Signature Genomics Laboratories Llc | Multiplex (+/-) stranded arrays and assays for detecting chromosomal abnormalities associated with cancer and other diseases |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
WO2011047257A1 (en) | 2009-10-16 | 2011-04-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for producing cyclic peptoid libraries |
NZ599866A (en) | 2009-11-06 | 2014-09-26 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
SI2521568T1 (en) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Plasma kallikrein binding proteins |
EP2531224B1 (en) | 2010-01-26 | 2019-06-05 | Bioregency, Inc. | Compositions and methods relating to argininosuccinate synthetase |
US20110229921A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS |
US11225655B2 (en) | 2010-04-16 | 2022-01-18 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
EP3508854A1 (en) | 2010-04-27 | 2019-07-10 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
SI2571532T1 (en) | 2010-05-14 | 2017-10-30 | Abbvie Inc. | Il-1 binding proteins |
ES2573108T3 (en) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Fibronectin-based framework proteins that have improved stability |
US9551714B2 (en) | 2010-06-25 | 2017-01-24 | Abbott Laboratories | Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
KR20130100118A (en) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | Dual variable domain immunoglobulins and uses therof |
US20130210663A1 (en) | 2010-08-04 | 2013-08-15 | Cizzle Biotechnology Limited | Methods and compounds for the diagnosis and treatment of cancer |
EP2428583A1 (en) | 2010-09-10 | 2012-03-14 | Bioftalmik, S.L. | Method of prognosis for the success of filtering surgery and for determining the progress of cicatrization |
BR112013008347A2 (en) | 2010-10-06 | 2016-06-14 | Bp Corp North America Inc | cbh variant polypeptides i |
JP6071886B2 (en) | 2010-10-14 | 2017-02-01 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Brain injury biomarkers |
US20120115244A1 (en) | 2010-11-09 | 2012-05-10 | Abbott Laboratories | Materials and methods for immunoassay of pterins |
KR20130133247A (en) | 2010-12-21 | 2013-12-06 | 애브비 인코포레이티드 | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
WO2012092376A2 (en) | 2010-12-31 | 2012-07-05 | Short Jay M | Comprehensive monoclonal antibody generation |
MA34948B1 (en) | 2011-02-07 | 2014-03-01 | Plexxikon Inc | COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF |
TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
ES2926988T3 (en) | 2011-03-15 | 2022-10-31 | X Body Inc | Antibody screening methods |
RU2013145890A (en) | 2011-03-15 | 2015-04-20 | Юниверсити Оф Юта Рисерч Фаундейшн | METHODS FOR DIAGNOSIS AND TREATMENT OF VASCULAR ASSOCIATED MACULOPATHY AND ITS SYMPTOMS |
HUE033008T2 (en) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
EP3418380B1 (en) | 2011-04-28 | 2022-05-25 | The Board of Trustees of the Leland Stanford Junior University | Identification of polynucleotides associated with a sample |
KR20140044329A (en) | 2011-05-12 | 2014-04-14 | 트래스래셔널 캔서 드럭스 파마 에스.엘. | Kiaa1456 expression predicts survival in patients with colon cancer |
EP2707389B1 (en) | 2011-05-12 | 2019-10-30 | The Johns Hopkins University | Assay reagents for a neurogranin diagnostic kit |
RU2631487C2 (en) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Kinases modulation and indications for its use |
EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2714084B1 (en) | 2011-06-02 | 2019-05-22 | Dyax Corp. | Fc RECEPTOR BINDING PROTEINS |
WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
MX2014004977A (en) | 2011-10-24 | 2014-09-11 | Abbvie Inc | Immunobinders directed against sclerostin. |
RU2014121043A (en) | 2011-10-24 | 2015-12-10 | Эббви Инк. | BISPECIFIC IMMUNO-BINDING AGENTS AIMED AGAINST TNF AND IL-17 |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
AU2012344155A1 (en) | 2011-11-28 | 2014-07-03 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Methods and kits for the prognosis of colorectal cancer |
TWI640537B (en) | 2011-12-05 | 2018-11-11 | X 染色體有限公司 | Pdgf receptor beta binding polypeptides |
WO2013092960A1 (en) | 2011-12-22 | 2013-06-27 | Fundacion Gaiker | Methods and kits for the diagnosis of colorectal cancer |
US8993248B2 (en) | 2011-12-31 | 2015-03-31 | Abbott Laboratories | Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use |
WO2013106886A1 (en) | 2012-01-20 | 2013-07-25 | Adelaide Research & Innovation Pty Ltd | Biomarkers for gastric cancer and uses thereof |
GB2500243A (en) * | 2012-03-15 | 2013-09-18 | Isogenica Ltd | Identifying members of immobilised peptide libraries comprising protein-DNA complexes |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2013190081A1 (en) | 2012-06-22 | 2013-12-27 | Proyecto De Biomedicina Cima, S.L. | Methods and reagents for the prognosis of cancer |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
US20150309036A1 (en) | 2012-08-16 | 2015-10-29 | The Trustees Of Columbia University In The City Of New York | Diagnostic Markers of Indolent Prostate Cancer |
MY172863A (en) | 2012-09-13 | 2019-12-13 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
WO2014072517A1 (en) | 2012-11-12 | 2014-05-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
EP2929351B1 (en) * | 2012-12-10 | 2019-10-09 | The University of Queensland | Cell-free biofragment compositions and related systems, devices, and methods |
AU2013202668B2 (en) | 2012-12-24 | 2014-12-18 | Adelaide Research & Innovation Pty Ltd | Inhibition of cancer growth and metastasis |
EP2951206A2 (en) | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
EP2953968B1 (en) | 2013-02-06 | 2018-07-25 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
US9267171B2 (en) | 2013-02-28 | 2016-02-23 | New York University | DNA photolithography with cinnamate crosslinkers |
JP6739329B2 (en) | 2013-03-14 | 2020-08-12 | アボット・ラボラトリーズAbbott Laboratories | HCV core lipid binding domain monoclonal antibody |
JP2016512241A (en) | 2013-03-14 | 2016-04-25 | アボット・ラボラトリーズAbbott Laboratories | HCVNS3 recombinant antigen for improved antibody detection and mutants thereof |
EP2968526A4 (en) | 2013-03-14 | 2016-11-09 | Abbott Lab | Hcv antigen-antibody combination assay and methods and compositions for use therein |
US9005901B2 (en) | 2013-03-15 | 2015-04-14 | Abbott Laboratories | Assay with internal calibration |
GB2584364A (en) | 2013-03-15 | 2020-12-02 | Abvitro Llc | Single cell bar-coding for antibody discovery |
US9157910B2 (en) | 2013-03-15 | 2015-10-13 | Abbott Laboratories | Assay with increased dynamic range |
EP4286853A3 (en) | 2013-05-10 | 2024-03-06 | Johns Hopkins University | Compositions for ovarian cancer assessment having improved specificity |
EP3739336B1 (en) | 2013-06-28 | 2022-05-11 | X-Body, Inc. | Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes |
EP3022322A4 (en) | 2013-07-17 | 2017-05-17 | The Johns Hopkins University | A multi-protein biomarker assay for brain injury detection and outcome |
CN105705947B (en) | 2013-09-23 | 2019-04-02 | X博迪公司 | For generating the method and composition of the bonding agent of confrontation cell surface antigen |
CA2943241C (en) | 2014-03-20 | 2023-09-19 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
DK3143138T3 (en) | 2014-05-13 | 2022-04-25 | Bioatla Inc | CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS |
CN107209188A (en) | 2014-06-27 | 2017-09-26 | 雅培制药有限公司 | Composition and method for detecting people Pegivirus 2 (HPgV 2) |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
CA2959786A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
SG11201702060VA (en) | 2014-09-15 | 2017-04-27 | Abvitro Inc | High-throughput nucleotide library sequencing |
US10222386B2 (en) | 2014-09-19 | 2019-03-05 | The Johns Hopkins University | Biomarkers of congnitive dysfunction |
BR112017009029A2 (en) | 2014-10-29 | 2018-02-06 | Abbott Lab | anti-hcv antibody detection assays of an individual using ns3 capture peptides |
KR20170084332A (en) | 2014-12-04 | 2017-07-19 | 노파르티스 아게 | Methods and compositions using klotho variant polypeptides |
US11543411B2 (en) | 2014-12-05 | 2023-01-03 | Prelude Corporation | DCIS recurrence and invasive breast cancer |
JP6383015B2 (en) * | 2015-01-22 | 2018-08-29 | アークレイ株式会社 | Target analysis chip and target analysis method |
EP3259594A4 (en) | 2015-02-20 | 2018-12-26 | The Johns Hopkins University | Biomarkers of myocardial injury |
CN107580603A (en) | 2015-02-24 | 2018-01-12 | 生物蛋白有限公司 | Condition active biological protein |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AU2016291558A1 (en) | 2015-07-10 | 2018-02-08 | West Virginia University | Markers of stroke and stroke severity |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
KR20180056701A (en) | 2015-09-23 | 2018-05-29 | 브리스톨-마이어스 스큅 컴퍼니 | Fast-off-rate serum albumin binding fibronectin type III domain |
SG11201804711RA (en) | 2015-12-07 | 2018-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
WO2017126479A1 (en) * | 2016-01-22 | 2017-07-27 | アークレイ株式会社 | Target analysis method and target analysis chip |
SI3455261T1 (en) | 2016-05-13 | 2023-01-31 | Bioatla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3246415A1 (en) | 2016-05-18 | 2017-11-22 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Methods for the prognosis of prostate cancer |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
WO2018089764A1 (en) | 2016-11-11 | 2018-05-17 | Ascendant Dx, Llc | Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and kawasaki disease |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
ES2688737A1 (en) | 2017-05-04 | 2018-11-06 | Universidad Del País Vasco / Euskal Herriko Unibertsitatea | METHOD TO DIAGNOSE UNSTABLE ATEROSCERTO PLATE (Machine-translation by Google Translate, not legally binding) |
CN111148849A (en) | 2017-05-26 | 2020-05-12 | 阿布维托有限责任公司 | High throughput polynucleotide library sequencing and transcriptome analysis |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
AU2018318435A1 (en) | 2017-08-16 | 2020-04-02 | Medimmune, Llc | Compositions and methods for treatment of atopic dermatitis and treatment selection |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
WO2019236632A1 (en) | 2018-06-04 | 2019-12-12 | Avon Products. Inc. | Protein biomarkers for identifying and treating aging skin and skin conditions |
WO2020056338A1 (en) | 2018-09-14 | 2020-03-19 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
US20220026444A1 (en) | 2018-11-26 | 2022-01-27 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease |
EP3674421A1 (en) | 2018-12-28 | 2020-07-01 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Methods for the prognosis of prostate cancer |
CA3138367A1 (en) | 2019-04-30 | 2020-11-05 | Encodia, Inc. | Methods for preparing analytes and related kits |
CN111041025B (en) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | mRNA targeting molecule based on combination of N-acetylgalactosamine polypeptide and preparation method thereof |
US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
CN111744019B (en) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | Mannose-based mRNA targeted delivery system and application thereof |
WO2022003146A1 (en) | 2020-07-03 | 2022-01-06 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Methods for predicting the risk of local invasion and/or metastasis induced by an antiangiogenic treatment |
WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599303A (en) * | 1983-12-12 | 1986-07-08 | Hri Associates, Inc. | Nucleic acid hybridization assay employing probes crosslinkable to target sequences |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5372930A (en) * | 1992-09-16 | 1994-12-13 | The United States Of America As Represented By The Secretary Of The Navy | Sensor for ultra-low concentration molecular recognition |
US5514543A (en) * | 1992-04-03 | 1996-05-07 | Applied Biosystems, Inc. | Method and probe composition for detecting multiple sequences in a single assay |
US5545698A (en) * | 1990-08-31 | 1996-08-13 | University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
US5545531A (en) * | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5643768A (en) * | 1989-10-05 | 1997-07-01 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
US5677196A (en) * | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5789208A (en) * | 1994-01-31 | 1998-08-04 | The Trustees Of Boston University | Polyclonal antibody libraries |
US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5843767A (en) * | 1993-10-28 | 1998-12-01 | Houston Advanced Research Center | Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions |
US5849878A (en) * | 1993-08-13 | 1998-12-15 | The Regents Of The University Of California | Design and synthesis of bispecific reagents: use of double stranded DNAs as chemically and spatially defined cross-linkers |
US5935793A (en) * | 1996-09-27 | 1999-08-10 | The Chinese University Of Hong Kong | Parallel polynucleotide sequencing method using tagged primers |
US5965133A (en) * | 1994-01-31 | 1999-10-12 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US5985575A (en) * | 1998-05-20 | 1999-11-16 | Wisconsin Alumni Research Foundation | Tethered function assay for protein function |
US6207446B1 (en) * | 1997-01-21 | 2001-03-27 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US6261804B1 (en) * | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US6436665B1 (en) * | 1999-08-27 | 2002-08-20 | Phylos, Inc | Methods for encoding and sorting in vitro translated proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69132843T2 (en) * | 1990-12-06 | 2002-09-12 | Affymetrix Inc N D Ges D Staat | Identification of nucleic acids in samples |
EP0562025B1 (en) | 1990-12-06 | 2001-02-07 | Affymetrix, Inc. (a Delaware Corporation) | Compounds and their use in a binary synthesis strategy |
AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
US6156501A (en) * | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
AU2253397A (en) * | 1996-01-23 | 1997-08-20 | Affymetrix, Inc. | Nucleic acid analysis techniques |
AU1115200A (en) * | 1998-10-13 | 2000-05-01 | Clontech Laboratories, Inc. | Nucleic acid arrays |
-
1999
- 1999-03-31 EP EP99916283A patent/EP1068356B8/en not_active Expired - Lifetime
- 1999-03-31 JP JP2000542484A patent/JP2002510505A/en active Pending
- 1999-03-31 US US09/282,734 patent/US6537749B2/en not_active Expired - Lifetime
- 1999-03-31 DE DE69933369T patent/DE69933369D1/en not_active Expired - Lifetime
- 1999-03-31 AT AT99916283T patent/ATE340870T1/en not_active IP Right Cessation
- 1999-03-31 IL IL13866899A patent/IL138668A0/en unknown
- 1999-03-31 CA CA002323638A patent/CA2323638A1/en not_active Abandoned
- 1999-03-31 WO PCT/US1999/007203 patent/WO1999051773A1/en active IP Right Grant
- 1999-03-31 AU AU34636/99A patent/AU3463699A/en not_active Abandoned
-
2003
- 2003-01-22 US US10/348,627 patent/US20030143616A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599303A (en) * | 1983-12-12 | 1986-07-08 | Hri Associates, Inc. | Nucleic acid hybridization assay employing probes crosslinkable to target sequences |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5643768A (en) * | 1989-10-05 | 1997-07-01 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5545698A (en) * | 1990-08-31 | 1996-08-13 | University Of Minnesota | Polyethylene glycol derivatives for solid-phase applications |
US5514543A (en) * | 1992-04-03 | 1996-05-07 | Applied Biosystems, Inc. | Method and probe composition for detecting multiple sequences in a single assay |
US5372930A (en) * | 1992-09-16 | 1994-12-13 | The United States Of America As Represented By The Secretary Of The Navy | Sensor for ultra-low concentration molecular recognition |
US5547835A (en) * | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
US5677196A (en) * | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5849878A (en) * | 1993-08-13 | 1998-12-15 | The Regents Of The University Of California | Design and synthesis of bispecific reagents: use of double stranded DNAs as chemically and spatially defined cross-linkers |
US5843767A (en) * | 1993-10-28 | 1998-12-01 | Houston Advanced Research Center | Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions |
US5789208A (en) * | 1994-01-31 | 1998-08-04 | The Trustees Of Boston University | Polyclonal antibody libraries |
US5965133A (en) * | 1994-01-31 | 1999-10-12 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5556752A (en) * | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5545531A (en) * | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US5935793A (en) * | 1996-09-27 | 1999-08-10 | The Chinese University Of Hong Kong | Parallel polynucleotide sequencing method using tagged primers |
US6258558B1 (en) * | 1997-01-21 | 2001-07-10 | The General Hospital Corporation | Method for selection of proteins using RNA-protein fusions |
US6207446B1 (en) * | 1997-01-21 | 2001-03-27 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US6214553B1 (en) * | 1997-01-21 | 2001-04-10 | Massachusetts General Hospital | Libraries of protein encoding RNA-protein fusions |
US6261804B1 (en) * | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US6281344B1 (en) * | 1997-01-21 | 2001-08-28 | The General Hospital Corporation | Nucleic acid-protein fusion molecules and libraries |
US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US5985575A (en) * | 1998-05-20 | 1999-11-16 | Wisconsin Alumni Research Foundation | Tethered function assay for protein function |
US6436665B1 (en) * | 1999-08-27 | 2002-08-20 | Phylos, Inc | Methods for encoding and sorting in vitro translated proteins |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040086883A1 (en) * | 2000-08-11 | 2004-05-06 | Hermann Gaub | Method and device for characterising and/or for detecting a bonding complex |
US20050084855A1 (en) * | 2001-06-01 | 2005-04-21 | Kerstin Blank | Method for determining an analyte |
US7700371B2 (en) | 2001-06-01 | 2010-04-20 | Arrowhead Research Corporation | Method for determining an analyte |
WO2005045075A2 (en) * | 2003-08-12 | 2005-05-19 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
US20050118570A1 (en) * | 2003-08-12 | 2005-06-02 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
WO2005045075A3 (en) * | 2003-08-12 | 2005-12-15 | Massachusetts Inst Technology | Sample preparation methods and devices |
US7541448B2 (en) | 2003-12-02 | 2009-06-02 | Roche Diagnostis Operations, Inc. | Oligonucleotides containing molecular rods |
EP1538221A1 (en) * | 2003-12-02 | 2005-06-08 | Roche Diagnostics GmbH | Oligonucleotides containing molecular rods |
US20050142598A1 (en) * | 2003-12-02 | 2005-06-30 | Dieter Heindl | Oligonucleotides containing molecular rods |
WO2007097740A3 (en) * | 2005-02-11 | 2007-11-01 | Massachusetts Inst Technology | Sample preparation methods and devices |
WO2007097740A2 (en) * | 2005-02-11 | 2007-08-30 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
EP1994209A2 (en) * | 2006-01-03 | 2008-11-26 | The President and Fellows of Harvard College | Small molecule printing |
EP1994209A4 (en) * | 2006-01-03 | 2013-11-13 | Harvard College | Small molecule printing |
US20110151510A1 (en) * | 2006-03-28 | 2011-06-23 | Fujitsu Limited | Functional molecule and manufacturing method therefor |
US9512171B2 (en) | 2006-03-28 | 2016-12-06 | Apta Biosciences Ltd | Functional molecule and manufacturing method therefor |
US20090099027A1 (en) * | 2007-08-23 | 2009-04-16 | Applied Biosystems Inc. | Methods of Modifying Support Surfaces for the Immobilization of Particles and the Use of the Immobilized Particles for Analyzing Nucleic Acids |
US20100086927A1 (en) * | 2008-07-23 | 2010-04-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
US8173198B2 (en) | 2008-07-23 | 2012-05-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
Also Published As
Publication number | Publication date |
---|---|
WO1999051773A9 (en) | 2000-02-03 |
ATE340870T1 (en) | 2006-10-15 |
EP1068356B8 (en) | 2007-01-03 |
US6537749B2 (en) | 2003-03-25 |
JP2002510505A (en) | 2002-04-09 |
US20020182597A1 (en) | 2002-12-05 |
DE69933369D1 (en) | 2006-11-09 |
CA2323638A1 (en) | 1999-10-14 |
EP1068356A1 (en) | 2001-01-17 |
EP1068356A4 (en) | 2001-09-05 |
WO1999051773A1 (en) | 1999-10-14 |
EP1068356B1 (en) | 2006-09-27 |
AU3463699A (en) | 1999-10-25 |
IL138668A0 (en) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6537749B2 (en) | Addressable protein arrays | |
AU779653B2 (en) | Methods for encoding and sorting in vitro translated proteins | |
US6413722B1 (en) | Polymer coated surfaces for microarray applications | |
EP0988398A1 (en) | Nucleic acid arrays | |
JP4388369B2 (en) | Sorting and immobilization system for nucleic acids using a synthetic binding system | |
US9266726B2 (en) | Method for making biochips | |
JP2001508308A (en) | Nucleic acid sequencing | |
US7049073B2 (en) | Double stranded nucleic acid biochips | |
US20030082571A1 (en) | Linear nucleic acid and sequence therefor | |
AU2004200234A1 (en) | Addressable protein arrays | |
JPWO2005001086A1 (en) | Immobilized mRNA-puromycin conjugate and uses thereof | |
US6908678B2 (en) | Plastic slides for the fabrication of biochips | |
JP2003500066A (en) | Detection system for the study of molecular interactions and its manufacture and use | |
US20100167955A1 (en) | Microarray including layer comprising dna molecule and method of manufacturing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COMPOUND THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHYLOS, INC.;REEL/FRAME:014313/0534 Effective date: 20031216 |
|
AS | Assignment |
Owner name: ADNEXUS THERAPEUTICS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:COMPOUND THERAPEUTICS, INC.;REEL/FRAME:018061/0643 Effective date: 20060620 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |